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  Abstract 
Technological advances in imaging and radiotherapy have led to significant improvement 
in the survival rate of breast cancer patients. However, a larger proportion of patients are 
now exhibiting the less understood, latent effects of incidental cardiac irradiation that 
occurs during left-sided breast radiotherapy. Here, we examine the utility of four-
dimensional computed tomography (4D-CT) for the accurate assessment of cardiac dose; 
and a hybrid positron emission tomography (PET) magnetic resonance imaging (MRI) 
system to longitudinally study radiation-induced cardiac effects in a canine model. 
Using 4D-CT and deformable dose accumulation, we assessed the variation caused by 
breathing motion in the estimated dose to the heart, left-ventricle, and left anterior 
descending artery (LAD) of left-sided breast cancer patients. The LAD showed 
substantial variation in dose due to breathing. In light of this, we suggest the use of 4D-
CT and dose accumulation for future clinical studies looking at the relationship between 
LAD dose and cardiac toxicity.  
Although symptoms of cardiac dysfunction may not manifest clinically for 10-15 years 
post radiation, PET-MRI can potentially identify earlier changes in cardiac inflammation 
and perfusion that are typically asymptomatic. Using PET-MRI, the progression of 
radiation-induced cardiac toxicity was assessed in a large animal model. Five canines 
were imaged using 13N-ammonia and 18F-fluorodeoxyglucose (FDG) PET-MRI to assess 
changes in myocardial perfusion and inflammation, respectively. All subjects were 
imaged at baseline, 1 week, 4 weeks, 3 months, 6 months, and 12 months after focused 
cardiac irradiation. To the best of our knowledge PET has not been previously used to 
assess cardiac perfusion following irradiation.   
The delivered dose to the heart, left ventricle, LAD, and left circumflex artery were 
comparable to what has been observed during breast radiotherapy. Relative to baseline, a 
transient increase in myocardial perfusion was observed followed by a gradual return to 
baseline. However, a persistent increase in FDG uptake was observed throughout the 
entire left ventricle, including both irradiated and less-irradiated portions of the heart.  
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In light of these findings, we suggest the use of this imaging approach for future human 
studies to assess mitigation strategies aimed at minimizing cardiac exposure and long-
term toxicity subsequent to left-sided breast irradiation.  
Keywords 
Radiotherapy, breast cancer, radiation-induced toxicity, cardiac imaging, respiratory 
motion, four dimensional computed tomography (4D-CT), positron emission tomography 
(PET), perfusion, inflammation, hybrid imaging.  
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Chapter 1  
1 Introduction 
This thesis deals with an important and prognostically significant side-effect of breast 
cancer treatment, specifically the cardiac effects on perfusion and inflammation of 
radiation therapy. We begin with an overview of radiation therapy for cancer treatment 
followed by a summary of the relevant literature on the topic of radiation induced cardiac 
toxicity. Brief explanations are provided with regards to the techniques employed to 
assess these effects in subsequent chapters. This chapter is concluded by highlighting the 
gaps in knowledge, relevant problems/questions to the area of study, and the 
hypothesis/aims of the thesis. 
1.1 Radiation therapy for the treatment of cancer 
In 2015, the Canadian Cancer Society reported approximately 80,000 Canadian deaths 
due to cancer. Although this is a very sobering statistic, the significant progress made in 
the last quarter century in diagnosing, understanding, and treating this disease is 
encouraging. Technological advances in medical imaging systems(1) have improved the 
ability to diagnose, plan treatments, and monitor response/recurrence in virtually every 
cancer type. Identification of the exact location of cancer sites, even for moving tumours 
situated in the lungs, is now possible and routine clinical practice. 
After diagnosis, cancer is typically treated through surgery, chemotherapy, and/or 
radiation therapy. Although this thesis provides less emphasis on surgery and 
chemotherapy, their integral role in the treatment of cancer should not be underestimated.  
Approximately two thirds of cancer patients will be treated with radiation (2). Radiation 
therapy can be delivered using two approaches 1) external beam radiotherapy, where a 
radioactive source originates outside the patient or 2) brachytherapy, where the 
radioactive source is implanted within the patient.Nearly 90% of patients treated with 
radiation, receive external beam radiotherapy(2), delivered via a linear accelerator 
(commonly referred to as a LINAC).  
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1.1.1 Linear Accelerators (LINACs) – General Overview 
The linear accelerator (LINAC) is used to accelerate charged particles (typically 4-25 
MeV electrons) that can be used to treat superficial tumours. Deeper lesions can also be 
treated using non-charged particles created after the kinetic energy of the electrons is 
converted into x-rays. Figure 1-1 is adapted from Podgorsak, et al(3) and highlights the 
major components of a typical LINAC.   
 
Figure 1-1: A schematic of a typical isocentric medical linear accelerator (panel A) 
and a photograph of a commercial unit (Varian Medical Systems; panel B). adapted 
from Podgorsak, 2005 (3) 
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In general, the forming of the treatment beam of radiation begins with the genesis of 
“free” electrons. Electrons are liberated from a cathode through a process of thermionic 
emission and accelerated through a perforated anode into the next major component of 
the LINAC, the accelerating waveguide. Inside the accelerating waveguide, the injected 
electrons interact with high powered radiofrequency fields. In the waveguide electrons 
can reach velocities greater than 99.9% of the speed of light. These high-energy electrons 
are then steered, through the use of magnets, towards an x-ray target located in the head 
of the LINAC.  The energy lost by the electrons during the collisions with the target 
produce high energy x-rays for treatment. Alternatively, the target can be retracted and 
electrons are allowed to exit the LINAC for electron beam therapy. The above is a very 
brief overview with regards to the inner workings of the typical medical LINAC, the 
following references provide a more detailed description(3, 4). 
The delivery of radiation therapy via LINACs has been significantly improved over the 
last 25 years and continues to improve rapidly (5, 6). Medical LINACs in both academic 
and smaller non-academic cancer centres now have the ability to shape/vary the intensity 
of the radiation beam and provide on board imaging. Figure 1-2 illustrates the progressive 
improvements in our ability to conform radiation doses to a tumour. The techniques 
available to achieve this conformity have been collectively termed intensity modulated 
radiation therapy (IMRT) and have been made possible through the addition of computer-
controlled multi-leaf collimator systems (MLC) in the head of the LINAC. The positions 
of the MLCs needed to achieve a desired dose distribution is obtained during the 
radiation treatment planning process through an inverse optimization algorithm(7).     
On board, fluoroscopic x-ray imaging and cone-beam computed tomography(8) systems 
have been primarily used to improve the ability to reproducibly set up patients on the 
treatment couch. Since RT is typically multi-fractionated, the day to day reproducibility 
is paramount for successful treatment. Through the use of on-board imaging, set-up 
uncertainty is now ≤ 5mm (9). Additionally, on board imaging can potentially provide 
more personalized treatment strategies, commonly referred to as adaptive radiation 
therapy(10). The goal of adaptive radiation therapy is to quickly and efficiently re-plan 
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and optimize each patient’s radiation treatment in response to volumetric and/or 
functional changes in their anatomy observed via imaging during the course of treatment.  
 
Figure 1-2: Prostate cancer radiotherapy 1935–2010. Prostate cancer irradiation is a 
good example of the improvement of radiotherapy technology over the past decades. 
By increasing the beam energy and the precision of the targeting, it was possible to 
escalate the dose to the prostate without exceeding the tolerance dose of healthy 
tissues; allowing the move from palliative irradiation to curative treatment. 
Abbreviations: 3D-CRT, 3D conformal radiotherapy; IMRT, intensity modulated 
radiotherapy; RT, radiotherapy. Reprinted with permission from Nature Review 
Clinical Oncology; Thariat J, et al. Nat. Rev. Clin. Oncol. 2012;10:52–60. 
The ultimate metric for assessing the effectiveness of these advances, is how they 
translate to improvements in the overall survival of cancer patients. One of the most 
encouraging examples can be drawn from the significant improvement in the survival rate 
of breast cancer patients (11) (see Figure 1-3). The five-year, 10-year, and 15-year 
survival rate for breast cancer is now 89%, 83%, and 78% respectively (11, 12). In 
addition to the improved conformity of radiotherapy delivery, this cohort of patients has 
also benefited from technological advances in medical imaging which have led to earlier 
diagnosis. An important caveat when interpreting these improvements in survival rates is 
the presence of known bias (~overestimation of 1.25 years) (13). This lead bias is due to 
the fact that breast cancer patients who have been diagnosed earlier will naturally live 
longer after diagnosis. The improved survival consequently leads to an increase in the 
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less understood long-term side-effects of cancer treatment. One clinically significant and 
heavily debated side effect of breast, lung, and esophageal cancer treatment is radiation-
induced cardiac toxicity (RICT)(14). The over-arching focus of this thesis is the negative 
effects of breast cancer radiotherapy on the heart. 
 
Figure 1-3: Five year survival percentage following breast cancer diagnosis from 
1975-2012. Obtained from Howlader N, et al. Surveillance, Epidemiology, and End 
Results Cancer Statistics Review, 1975-2011. Natl. Cancer Inst. 2014.   
1.2 Left-sided breast cancer radiotherapy 
The five year survival statistic of Canadian breast cancer patients is above 80%; however, 
breast cancer still accounts for nearly 25% of the total yearly female cancer 
mortalities(15). Although this may seem counter-intuitive, it is explained by the large 
incidence rate of breast cancer; statistically, 1 in 4 females will be diagnosed with breast 
cancer in their lifetime(15). Although patients are responding well to treatment, the large 
volume of diagnosed patients leads to a significant number of mortalities even with cure 
rates at ~80%. 
Breast cancer is typically treated with a combination of surgery, chemotherapy, and/or 
radiation therapy. The radiotherapy for breast cancer is most commonly delivered using a 
medical LINAC. The primary goal for breast cancer radiotherapy planning is to deliver 
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the clinically prescribed radiation dose (~50 Gy) to the entire breast or if following 
mastectomy, the entire chest wall. The radiation is typically delivered using two 
sequential radiation beams oriented such that they are tangential to the chest wall and 
opposed to each other, commonly referred to as tangential parallel-opposed or POP 
arrangement (see Figure 1-4). A secondary goal of radiotherapy planning is to avoid 
irradiating the surrounding healthy organs. However, this cannot always be achieved 
when organs are in close proximity to the treatment site.  
 
Figure 1-4: A transverse computed tomography (CT) image of a left-sided breast 
cancer patient. The radiation dose distribution from treatment is overlaid onto the 
left breast. The entire heart, left ventricle only, and left anterior descending artery 
are contoured in magenta, yellow, and blue respectively. The typical orientation of 
the tangential parallel opposed beam arrangement is indicated by the red arrows. 
For left-sided breast cancer patients, the lung, heart, and major coronary arteries tend to 
be co-irradiated due their close proximity to the anterior chest wall (Figure 1-4). A 
recently published systematic review reported the mean dose to the hearts of left-sided 
breast cancer patients to be 5.4 Gy and as high as ~8Gy if the treatment includes the 
internal mammary chain(16).  Darby et al reported that the rate of a major coronary event 
7 
 
 
 
increased linearly by 7.4% per Gy with no apparent threshold below which there is no 
risk(17). The relative risk of cardiac toxicity due to radiation is also considerably 
amplified by the presence of pre-existent risk factors such as diabetes, smoking, and 
chemotherapy (17). Comparisons between left-sided and right sided breast cancer 
patients in terms of cardiac toxicity are essential in understanding the effects of radiation 
isolated from the concomitant factors such as chemotherapy and more conventional 
cardiac risk factors (see Figure 1-5). Correa et al, reported clinically significant heart 
disease developed  in 59% of left-sided breast cancer patients compared to only 8% in 
right-sided breast cancer patients(18), 70% of which were in the left anterior descending 
artery (LAD) territory (predominately in the middle and distal segments).  
 
Figure 1-5: A comparison of left and right sided breast cancer patients regarding 
the presence of clinically significant coronary artery disease 10 -15 years following 
radiotherapy treatment. Proportions are obtained from Canadian Cancer Statistics, 
2015 and Correa CR, et al. J. Clin. Oncol. 2007(18).   
The evidence for the harmful effects of radiation on the heart is supported by numerous 
studies looking at clinical endpoints such as cardiac mortality and/or myocardial 
infarction in cancer patients and atomic bomb survivors(14, 16, 17, 19–22). Irradiation of 
the heart can result in a myriad of known cardiac and vascular pathologies; however, the 
underlying mechanisms and progression are not yet well understood. The future 
management and prevention of radiation-induced cardiac toxicity will require close 
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collaboration between the departments of oncology and cardiology.  As a result, a new 
‘hybrid’ discipline, termed cardio-oncology is beginning to emerge(23).   
1.3 Radiation induced cardiac toxicity: Clinical Endpoints 
There are several known clinically significant side-effects to cardiac irradiation. A 
detailed review of the literature is provided by Gagliardi, et al (14). The most common 
clinical endpoints that have been associated with cardiac irradiation are; pericarditis, 
myocardial infarction, valvular disease, congestive heart failure, and coronary artery 
disease. Some of these endpoints also occur in a high proportion of older patients without 
cardiac irradiation, making conclusions difficult without the use of non-irradiated control 
groups. In general, trials comparing irradiated and non-irradiated subjects for the above 
endpoints have shown relative risks ranging from 1.2 to 3.5 for those treated with 
radiation (14). 
1.3.1 Acute and chronic pericarditis 
Pericarditis is inflammation within the thin membrane that encloses the heart, referred to 
as the pericardium. Patients with pericarditis often suffer from chest pain. Generally, the 
disease will clear up naturally within a few days to weeks, once the inflammatory process 
resolves, although the length of the active process will vary depending on the inciting 
stimulus for inflammation. In rare cases surgery is needed to prevent complications. 
A longitudinal analysis report on the incidence of pericarditis in  women treated with 
radiotherapy for breast cancer(22) showed a pericarditis relative  incidence ratio of 1.61 
between the left-sided vs right-sided breast cancer patients. It should be noted that 
patients included in the above study were treated in the late 70’s and followed for up to 
30 years post-radiotherapy. Current methods for breast irradiation have improved 
significantly and as a result pericarditis is now an uncommon side effect of breast cancer 
radiotherapy. Acute pericarditis typically develops a few weeks following high exposure 
levels to the heart (≥ 36 Gy). These exposure levels are not typically observed in the 
breast cancer population but can sometimes occur for patients with tumours located 
within the mediastinum.       
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1.3.2 Myocardial infarction 
Myocardial infarction or more commonly called a heart attack refers to damage or death 
to a portion of the myocardium. Myocardial damage and/or death are usually the result of 
an occluded coronary artery preventing the flow of blood to the myocardium.  
The incidence ratio for acute myocardial infarction between left-sided and right-sided 
breast cancer patients is reported as 1.22, with 95% confidence interval between 1.06-
1.42(22). As previously mentioned these incidence ratios may be inflated due to higher 
exposure levels to the heart observed using older treatment technology. Literature using 
more modern treatment methods are rare due to the latency (>15 years) for myocardial 
infarction to develop following irradiation. A study of >14,000 long-term childhood 
cancer survivors receiving radiotherapy (heart doses > 5Gy) have shown a hazard rate of 
2.4 for myocardial infarction compared to matched non-irradiated cancer survivors(24). 
1.3.3 Valvular Disease 
Valvular disease following cardiac irradiation can lead to valve stenosis and/or 
regurgitation. Valve stenosis refers to a heart valve that does not fully open. This leads to 
increased load on the heart to pump blood through the narrow opening of the stenosed 
valve. Valve regurgitation refers to “leaky” valves that do not close properly causing 
additional strain on the heart to pump blood.  
An incidence ratio 1.54 for valvular disease between left-sided and right-sided breast 
cancer patients has been previously reported(22). Radiation related valvular abnormalities 
are more commonly observed in Hodgkin’s lymphoma survivors(25) than in breast 
cancer survivors as Hodgkin’s patients will often receive high dose mediastinal radiation. 
Valvular disease can be expected following heart doses >25 Gy(26).  
1.3.4 Congestive heart failure 
Damage to the myocardium most commonly caused by myocardial infarction can lead to 
reduced ability for the heart to contract/relax; this is referred to as congestive heart 
failure. 
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An increased incidence of congestive heart failure (incidence ratio = 7.4) has been 
observed following cardiac irradiation during the treatment of Hodgkin’s lymphoma(27). 
Increased risk of congestive heart failure following breast cancer radiotherapy has only 
been shown for early treatment techniques between 1970 and 1986(28). Heart doses 
<7Gy do not appear to result in an increased risk of congestive heart failure(29). 
1.3.5 Coronary artery disease 
Coronary artery disease refers to significant blockage of the coronary arteries leading to a 
disruption in blood flow to the heart. The source of the blockage is typically referred to as 
an atherosclerotic plaque. The atherosclerotic process is still not fully understood, Libby, 
et al provide a comprehensive review of the topic(30).  
Harris, et al, showed that left-sided breast cancer patients treated between 1977-1994 had 
a significantly greater risk of coronary artery disease than right-sided patients(31). 
Coronary artery disease is believed to be the predominant clinical endpoint following 
cardiac irradiation(32). Experimental studies provide evidence for two interesting 
hypotheses; 1) radiation causes an acceleration of the atherosclerotic process(33) and, 2) 
the resulting atherosclerotic plaques are of a phenotype that is more prone to rupture(33). 
The most common theme in the clinical end-points discussed above is that the 
progression towards them is slow (> 10 years following irradiation). In order to study the 
progression of radiation induced cardiac toxicity in a timelier manner, sub-clinical end-
points in asymptomatic patients and/or animal models need to be used. In addition to 
improved understanding of the disease progression, identifying predictive sub-clinical 
endpoints may open a window for early interventions that can protect breast cancer 
patients from the life threatening side effects discussed above. 
1.4 Radiation induced cardiac toxicity: Subclinical 
Endpoints 
More subtle changes will surely precede the life threatening clinical endpoints mentioned 
in the previous section. In this thesis, subclinical endpoints refer to these subtle changes if 
they can be detected non-invasively in humans. Experimental studies in animal models 
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play a pivotal role in identifying subclinical endpoints that can be used to monitor and 
then potentially augment radiation treatment to reduce the risk of radiation induced 
cardiac toxicity.  We begin with a brief introduction of the interaction of ionizing 
radiation on biological tissue; this area of study is commonly referred to as radiobiology. 
Our focus is not to provide a comprehensive review of radiobiology, but rather we aim to 
highlight areas most relevant to radiation induced cardiac toxicity. A more complete 
review of radiobiology is provided by Hall and Giaccia(34).   
1.4.1 Radiobiology primer 
The study of the effects of ionizing radiation on living organisms began almost 
immediately after Röntgen’s discovery of the x-ray in 1895. The biological effects 
observed following irradiation are primarily a result of DNA damage. Ionizing radiation 
can either directly or indirectly (through the genesis of highly reactive oxygen species) 
cause breaks in the DNA. Consequently, the cell’s natural repair mechanisms respond to 
the damaged DNA leading to 1 of 3 potential outcomes: 1) the cell successfully repairs 
the DNA; 2) the cell cannot repair the damage and responds by initiating apoptosis; 3) the 
cell incorrectly repairs the DNA resulting in a mutated living cell that may have an 
altered role within the body. This cascade provided the foundation for the fundamental 
law of radiobiology, “law of Bergonie and Tribondeau”(35). In general, the law 
designates organs/cells with low mitotic vs high mitotic activity to be considered 
radiation-resistant and radiation-sensitive, respectively. Additionally, the law states that 
radiation sensitivity is inversely proportional to the cell’s differentiation status. The heart 
and the blood vessels have been shown to be composed of highly differentiated cells with 
low mitotic activity. Annual cardiomyocyte turnover is less than 1% (36) in comparison 
to the intestines and lungs which have 100% turnover in just a few days and months, 
respectively (37). This is counter-intuitive considering the vast amount of 
epidemiological evidence presented previously with regards to the heart’s apparent 
sensitivity to radiation, although the clinical effects are generally not observed for several 
years.  As such, the radiobiology of the heart and vasculature follow a less common and 
less understood cascade towards radiation injury. 
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1.4.2 Radiobiology of the vasculature 
The vasculature, specifically the endothelial cells lining the lumen of blood vessels are 
considered highly differentiated cells with low mitotic activity. Evidence exists that 
radiation injury to cells does not just follow the typical DNA repair cascade but may also 
originate at the cell membrane.  Radiation has been shown in vitro and in vivo to initiate 
the hydrolysis of the cell membrane resulting in cell signaling of apoptosis(38). The same 
apoptotic signal mediator has also been observed in the heart during myocardial 
ischemia(39). The effects of radiation on the cellular membrane often results in 
alterations to the attachment, morphology, and continuity of the endothelial cell 
monolayer lining the vasculature(40).  
The majority of these alterations result in potential subclinical endpoints such as  
increased vascular permeability, fibrosis, and/or inflammation(41, 42). Changes in 
vascular permeability of the microcirculation can and has been previously assessed in 
breast cancer patients through the use of perfusion imaging. However, results from 
human studies using single photon emission computed tomography (SPECT) following 
breast cancer radiotherapy are inconclusive. Zellars et al, reports regions of increased and 
separate regions of decreased perfusion(43). Other studies have shown reductions in 
cardiac perfusion following radiotherapy  in ~50% of left sided breast cancer patients(44, 
45). Chung et al, did not observe any perfusion defects 6 months following left-sided 
breast radiotherapy(46). Lawrence et al reported that the incidence of new perfusion 
defects 6, 12, 18, and 24 months after radiotherapy was 27%, 29%, 38%, and 42%, 
respectively(47). Potential technical reasons for disagreement are presented in subsequent 
sections.  
Irradiation of the vascular endothelium has been shown to activate transcription factors 
that lead to pro-inflammatory, pro-coagulation, and leukocyte adhesion (33, 48–51). 
These studies in mice have shown that focal cardiac irradiation leads to an acceleration of 
the atherosclerotic process with plaque phenotypes prone to rupture. Gabriels et al, have 
shown that high doses to the heart (>16 Gy) induce a cell signaling cascade towards 
fibrosis, whereas low doses (~2 Gy) trigger an initial “survival response”, encouraging 
cellular growth, development, and proliferation(49). In mice, increases in endothelial cell 
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surface markers related to inflammation and proliferation can remain elevated up to 20 
weeks post irradiation (49, 52). Through the use of nuclear imaging, myocardial fibrosis 
and inflammation can also be assessed non-invasively in breast cancer patients following 
radiotherapy. However, to the best of our knowledge it has not yet been attempted. 
In light of the findings above, macrovascular and microvascular functional imaging is a 
logical target for monitoring the progression of radiation induced cardiac toxicity in 
humans. Vascular imaging may also play a role in assessing the efficacy of advanced 
radiation delivery strategies used to mitigate cardiac toxicity. 
1.5 Advanced radiation delivery strategies for mitigation 
1.5.1 Standard breast cancer radiotherapy 
The commonly used setup prior to irradiation is as follows; breast cancer patients are 
typically set-up in the supine position with arms extended above the head. A breast board 
is used for patient immobilization. Radio-opaque markers are typically used to help 
identify clinical boundaries of the targeted breast volume. The typical prescription dose is 
50 Gy in 25 fractions. Beam energies are typically between 4 – 10 MV; however, mixed 
beams, beams with higher energies, and local boosts can be used to ensure sufficient 
target coverage and minimize the incidence of local recurrence. 
The tangential parallel opposed technique for breast irradiation begins with a free-
breathing computed tomography scan that is used for treatment simulation. Tangential 
beams are used to target the breast volume and the beams are angled to minimize the 
divergence of the beam into the heart. A recently published meta-analysis showed that the 
mean heart dose using standard tangential fields can vary considerably (2.5 - 11.18 
Gy)(53).   
Additionally, intensity modulated radiation therapy (IMRT) can be used for treatment. 
IMRT beams vary in intensity to produce non-uniform fluency, allowing for greater 
conformity to target structures while reducing the dose to specified avoidance structures. 
For more degrees of freedom, IMRT can also be delivered in an arc, either with 
volumetric modulated arc therapy (VMAT) or with Tomotherapy. The previously 
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mentioned meta-analysis showed that mean heart doses using IMRT can also vary 
considerably (1.1 - 13.4 Gy)(53). 
Several modifications and alternatives to the traditional tangential parallel opposed beam 
arrangement have been proposed to reduce the amount of heart exposure during breast 
radiotherapy. The modifications primarily employ respiratory motion management 
strategies to minimize heart dose during radiotherapy. Additional, proposed alternatives 
to the standard treatment are brachytherapy, proton radiotherapy, and treating patients in 
the prone position. Currently there has not been any consensus regarding the “best 
approach”. The reasons for the lack of consensus and other key findings from the 
published literature are summarized below. 
1.5.2 Respiratory motion management during radiotherapy 
Modern day LINACs can be automatically triggered such that the beam of radiation is 
only delivered at specific portions of a patients breathing cycle. The three most 
commonly used respiratory triggers are abdominal strain gauges, video tracking of an 
external marker, and spirometry(54). The abdominal strain gauge, commonly referred to 
as the bellows system (Philips Medical Systems, Cleveland, USA) is tightly fastened to a 
patient’s abdomen, below the diaphragm. A patient’s respiratory trace is obtained by 
measuring changes in the pressure exerted by the breathing induced motion of diaphragm 
against the bellows system. Another approach is video monitoring of an external marker 
secured to the patient’s abdomen. This system is commercially referred to as the real-time 
position management system (Varian RPM system, Varian Medical Systems, Palo Alto, 
USA). The motion of the external marker follows the same principle described for the 
bellows device.  The third approach uses a spirometer to obtain a respiratory signal by 
measuring the volume of air entering and exiting the lungs. This system is commonly 
referred to as active breathing control (ABC). These systems are commonly used for 
triggering the LINAC to specific parts of a patients breathing cycle.  They are also used 
to reduce respiratory motion artifacts in tomographic imaging, specifically for lung 
cancer patients. It should be noted that these signals are only surrogates of internal organ 
motion and require validation as deviations have been reported (55). The application of 
these systems regarding reducing heart exposure during radiotherapy is principled in that 
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the heart is typically furthest from the breast during the end of inspiration. By triggering 
the beam on at the end of inspiration, the added separation between the breast and heart 
leads to a significant reduction in cardiac exposure. 
1.5.3 Inspiratory gating and breath-holds during left-sided breast 
radiotherapy 
The use of breath-holds during treatment, specifically deep-inspiration breath-holds have 
been shown to significantly reduce the mean heart dose in breast cancer patients by 40% 
(56). With regards to the deep inspiration breath-hold techniques, concern exists with 
regards to compliance and inefficiency in terms of time needed to train patients prior to 
treatment. In light of this, Korreman et al, proposed the use of inspiratory gating while 
the patient is freely breathing to avoid the need for patient training (57). Their study has 
shown that the dose reduction to the heart and LAD is not statistically different between 
deep-inspiration breath-holds vs inspiratory gating during free-breathing.  It should be 
noted that both breath-hold and gated methods do not account for the contractile motion 
of the heart itself. Wang, et al has shown that this motion may be negligible for the heart 
but not for the LAD (58). To account for cardiac motion, their study suggests that 
treatment plans should maintain at least a 5 mm margin between the posterior edge of the 
radiation field and the LAD. 
The use of gating and breath-holds consistently results in reduced mean heart dose; 
however, a recent clinical trial unexpectedly reported a worsening in cardiac perfusion in 
the apex of the left ventricular compared to standard treatment(43). The authors of the 
study suggest that although the motion management approaches reduce mean heart dose, 
they may cause a repositioning of the heart such that critical sub-structures such as the 
LAD may receive higher doses.   Thus, although the mean heart dose is often cited, it 
may not be an appropriate metric for the assessment of these treatment strategies. Several 
studies suggest that doses to the LAD may be more appropriate (18, 59) for predicting 
cardiac toxicity. Currently there is no clinical consensus as to a means of stratifying 
patients most likely to benefit from gating/breath-hold treatments. 
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1.5.4 Brachytherapy for the treatment of breast cancer 
Brachytherapy refers to a type of radiation treatment in which a source of radiation is 
placed near or within the area being treated. Brachytherapy has the benefit of being able 
to deliver high doses of radiation with very rapid fall-off in dose to tissues not 
immediately adjacent to the source. Placement of the radioactive sources is performed in 
the operating room with the aid of image guidance. The sources are typically “after-
loaded”, meaning that a catheter is first placed at the target position then the sources are 
automatically advanced through the catheter and loaded into position. The dose 
distribution for a given source can be altered by changing their positions within the target 
and/or changing the duration they are loaded (referred to as dwell time). Several 
brachytherapy approaches have been proposed for early stage breast cancer patients (60–
63); however, the most promising results are for the multi-catheter interstitial 
brachytherapy approach(62, 63). In comparison to standard radiotherapy, brachytherapy 
can significantly reduce both the maximum dose and the total volume of the heart that is 
irradiated during treatment(62). More importantly, this reduction in dose to the heart can 
be achieved without compromises in local control/rate recurrence at least 5-years post 
treatment(63).  The use of brachytherapy for the treatment of early stage breast cancer is 
commonly referred to as accelerated partial breast irradiation. In addition to the reasons 
mentioned above, accelerated partial breast irradiation is an attractive alternative to the 
standard treatment since it can shorten the course of treatment from 3-7 weeks to 2-5 
days. Unfortunately, this technique has only shown comparable control rates for early 
stage breast cancer patients with no lymph node involvement (stages 0, I, and IIa) (63). 
Accelerated partial breast irradiation can also be delivered intra-operatively (61); 
however this approach was shown to result in higher proportion of recurrence then the 
standard technique. Additionally, stereotactic external beam radiotherapy has been used 
as an attractive alternative for the delivery of accelerated partial breast irradiation as this 
approach is non-invasive and significantly easier to implement clinically (64). This 
approach has shown comparable local control to the standard (1.5% recurrence at 5 
years); however poor cosmetic outcomes are typically reported with external beam 
radiotherapy. 
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1.5.5 Breast cancer treatment in the prone position 
Another proposed approach for reducing cardiac irradiation during breast cancer 
treatment is to treat the patient lying prone on the treatment couch (65–67). With the 
patient lying in the prone position, more separation can be achieved between the heart 
and the breast. Kirby, et al has shown that significant reductions in dose to the LAD 
(mean dose reduction ~6 Gy; max dose reduction ~30 Gy) can be achieved(66). 
However, generally these reductions are only observed in patients with larger breast 
volume (>1000 cm3). Furthermore, treatment in the prone position was shown to be 
detrimental in women with smaller breast volume since in the prone position the 
separation between the heart and the chest wall is reduced. Conversely, Lymberis, et al 
reported that most women benefited from the prone treatment position regardless of 
breast size; however, doses to the LAD were not reported in this study(65). Further study 
is needed to provide guidelines for ensuring reproducible day to day patient setup prior to 
widespread adoption in the clinic. 
1.5.6 Breast cancer treatment using proton radiotherapy 
External beam radiotherapy is typically carried out with LINACs that produce either x-
rays or electrons; however, there is considerable interest in the use of heavier particles 
such as protons for breast cancer radiotherapy in order to reduce the dose to the heart(68–
71). Galland-Girodet et al, reported 0 Gy mean dose  and only 4 Gy max dose to the heart 
using protons for accelerated partial breast irradiation (72). Proton radiotherapy is 
capable of reducing dose deposition to healthy tissues situated distal to the target due to 
their superior dose deposition characteristics in comparison to photons and electrons. 
However, similar to photon radiotherapy, high skin dose and poor cosmetic outcomes are 
often reported (72).  The radiotherapy comparative effectiveness trial (RADCOMP) has 
been funded to compare the effectiveness of proton vs photon radiotherapy for breast 
patients (NCT02603341). Identifying whether or not protons can reduce cardiac mortality 
after breast cancer is one of the RADCOMP trial’s primary goals. Proton therapy is 
largely limited by the considerable amount of capital needed to create a medical proton 
accelerator. Thus only a few institutions have them for clinical use. Although upfront 
capital costs are high, reported estimates of the cost per treatment using protons shows 
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only a 5% increase in comparison to the cost of a 6 week course of standard tangential 
whole breast irradiation(68).  
Currently there is no consensus with regards to how a center should identify which left-
sided breast cancer patients are most likely to benefit from these advanced techniques 
which are generally more resource intensive and time consuming that the standard 
treatment. Additionally, long-term assessment of these novel strategies is still needed. 
Long-term follow-up studies are currently in place and are most ideal since radiation 
induced cardiac toxicity is a latent side-effect (typically 10-15 years post radiation). 
However, with the result from future studies pending,  diagnostic and functional cardiac 
imaging has been suggested to monitor the evolution and progression of radiation 
induced cardiac toxicity at earlier time points(73, 74). 
1.6 Advanced cardiac imaging of radiation-induced injury 
The potential effects of radiation on the heart can be imaged non-invasively through 
echocardiography, computed tomography (CT), nuclear tomographic imaging, and 
magnetic resonance imaging (MRI), each with relative strengths in assessing different 
parameters of radiation-induced injury. Their previous and potential role for studying 
radiation-induced cardiac toxicity is discussed below. 
1.6.1 Echocardiography 
Echocardiography can produce both 2-dimensional and 3-dimensional images of the 
heart. In general, images are produced after an ultrasonic pulse is emitted from an 
ultrasonic transducer through the specimen to be imaged. Ultrasonic echoes produced at 
the interfaces between different tissue types are acquired by the transducer and used for 
image reconstruction. In addition to images, the Doppler Effect can be utilized to obtain 
functional information such as blood flow and regional strain. Fenster, et al provides a 
more detailed and technical review of ultrasound imaging(75). 
Echocardiography has shown decreased myocardial systolic deformation (strain) in the 
left sided breast cancer patients as early as 2 months and up to 14 months post 
irradiation(76, 77). Regional changes were observed compared to baseline measures; 
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however, they were not statistically correlated with regional dose.  Unfortunately, the 
authors did not provide a patho-physiological mechanism for the observed reduction in 
myocardial strain. The overall clinical consequences of reductions in myocardial strain 
due to irradiation require further investigation. 
1.6.2 Computed Tomography (CT) 
Computed tomography imaging can provide high resolution cardiac images (~ 1mm 
isotropic voxels) and anatomic information such as the extent of coronary stenosis and 
functional information such as regional myocardial perfusion. Additionally, CT images 
can be used to accurately calculate doses from radiotherapy. CT based dose calculations 
are possible because the image signal intensity is directly related to tissue electron 
density (78). CT images are acquired by detecting the transmission of kilovoltage (kV) 
photons as they pass through a sample. Rotating the photon source and detector around 
the specimen gives multiple projections that can be later reconstructed into a 2-
dimensional (2D) image. A 3-dimensional (3D) volume can be obtained by longitudinally 
advancing the couch of the CT scanner while acquiring projections, commonly referred 
to as helical CT. Each set of projections is reconstructed into an image “slice” through 
the sample. For those interested, Johns and Cunningham provide a more comprehensive 
description of CT imaging (79).   
Cardiac CT studies of radiation induced cardiac toxicity are limited to microCT studies in 
mice(80) and Hodgkins survivors (81, 82). For left-sided breast cancer patients, the role 
of CT has been primarily reserved for quantifying the delivered dose to the heart and the 
LAD following standard and more advanced radiotherapy techniques (83, 84).  
Calculating the dose to heart, left ventricle, and LAD from standard helical CT imaging is 
challenging since this technique does not capture the motion of the heart or the LAD. 
Standard helical CT scanners used for breast radiotherapy planning do not have the 
temporal resolution to acquire artifact free, real-time images of internal organ motion due 
to respiration. This also poses a major challenge for treating tumor sites subject to 
respiratory motion such as the lung or liver. This problem is typically addressed through 
the use of a longer duration helical CT scan in which the pitch of the couch is slowed 
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such that multiple images can be acquired at the same slice position. Through the use of a 
breathing motion surrogate, the images can be retrospectively sorted to specific portions 
of the breathing cycle. This technique is commonly referred to as 4D-CT imaging(85, 
86). However, 4D-CT is not part of the current standard of care for breast cancer patients 
and only few studies have partially examined its utility for assessing cardiac dose 
associated with breast radiotherapy (83, 84, 87, 88). The use of 4D-CT imaging also 
allows for the estimation of dose distributions that have been “blurred/warped” in 
accordance to the motion of the internal anatomy. This warping of dose is commonly 
referred to as 4D dose accumulation (89). Unfortunately, adoption of 4D dose 
accumulation in clinics today is primarily hindered by challenges associated with proper 
validation of the accuracy of the dose deformation(90).    
In comparison to all the other imaging modalities, CT is the most widely available and 
extensively used in day to day cancer radiotherapy. Thus the emergence of functional 
cardiac CT perfusion may have a key role in future radiation induced cardiac toxicity 
trials(91). Quantitative cardiac CT perfusion has been recently validated using 
microspheres in porcine model of myocardial infaction(92). In comparison to gold-
standard measurement (microspheres), CT perfusion is strongly correlated with the gold-
standard measurement (R = 0.81), however, the method tends to overestimate perfusion 
by 20-25% due to beam hardening artifact caused by the contrast agent within the LV.    
1.6.3 Nuclear tomographic imaging 
Nuclear tomographic imaging has been used extensively to study cardiac pathology and 
in the routine clinical management of cardiovascular disease (93). In general, nuclear 
imaging is performed after a radio-isotope is injected into or inhaled by the patient. The 
radio-isotopes used in nuclear imaging are commonly referred to as radio-tracers. 
Different tracers tend to be specific to different biochemical pathways that occur within 
the body. The emitted radio-activity from the tracers can be detected by the imaging 
system after and/or during its distribution within the body. Tomographic image 
reconstruction algorithms are used to convert the emitted signal from within the body into 
images. The pixel intensity of the reconstructed images is proportional to the radio-tracer 
concentration in that region. The two most commonly used nuclear imaging systems are 
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single photon emission computed tomography (SPECT) and positron emission 
tomography (PET). There are many differences between SPECT and PET imaging 
systems, however, many of these differences are initially rooted in the fact that they use 
different types of radio-isotopes. In SPECT, the radio-isotopes are gamma-emitters; in 
PET, the radio-isotopes are positron emitters. A comprehensive description of these 
techniques is provided by Cherry, et al (94). To date, the use of nuclear imaging for the 
assessment of radiation-induced cardiac toxicity has been limited to SPECT myocardial 
perfusion, ejection fraction, and multigated acquisition studies. 
1.6.3.1 SPECT imaging of radiation-induced cardiac toxicity 
SPECT myocardial perfusion imaging is typically performed using thallium ( 201Tl) 
labelled or technetium (99mTc) labelled radio-tracers (95). Both of these tracers become 
metabolically trapped within the myocardium and their distribution within the heart is 
proportional to the regional myocardial blood flow. Thallium is an analog to potassium 
and is actively transported into cells through the sodium potassium pump. Unlike 201Tl, 
99mTc does not have a natural biochemical affinity for the myocardium. For this reason, 
99mTc is bound to a molecule with some cardiac affinity (typically sestamibi or 
tetrofosmin). Sestamibi and tetrofosmin are positively charged molecules that enter the 
intracellular space via passive transport and accumulate in the mitochondria of cardiac 
cells(96).   
Numerous studies have reported myocardial perfusion defects following left-sided breast 
cancer radiotherapy(18, 43, 45–47, 59, 97–99). An often cited finding was the ability to 
stratify patients most likely to present with perfusion defects by the volume of the heart 
irradiated with 25 Gy or more (47). Marks et al, studied a cohort of 114 patients treated 
between 1998 -2001. The patients were followed using SPECT perfusion imaging 
between 6 to 24 months post radiotherapy. In this study, new perfusion defects occurred 
in more than half of left-sided breast cancer patients with more than 5% of the heart 
irradiated by 25 Gy or more(47). These defects were typically observed 1-2 years post 
radiotherapy, however, in a smaller proportion of patients (< 30%), defects as early as 6 
months post irradiation were observed. The perfusion defects tend to be isolated to 
myocardial regions irradiated by at least 25 Gy. For left-sided breast cancer patients, this 
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tends to be the area of the heart supplied by the LAD (59). Similar findings are echoed in 
many of the other SPECT studies, however, not all studies observed cardiac perfusion 
defects. Sioka et al, compared 28 left and 18 right sided breast cancer patient treated 
between 1998 – 2010  using SPECT with a median follow-up of 40 months (45). 
Although the study found a difference between age-matched controls vs breast cancer 
patients, no differences were observed between left and right-sided patients. This lack of 
difference may be attributed to the small number of patients in the comparison. A recent 
study of 32 left-sided breast cancer patients with pre and 1 year follow-up SPECT, did 
not show any significant differences in perfusion or ejection fraction (46). The 
discrepancy between the findings from this study and the previous studies may be 
attributed to the lower mean heart dose or the shorter follow-up (1 year, 2.8 Gy (46) vs 40 
months,  ~7.7 Gy(45)). It appears that at the lower heart doses observed using modern 
radiotherapy techniques, SPECT cardiac imaging studies cannot identify a relationship 
between dose and defects until 3-6 years following treatment (100). This delay impedes 
our ability to understand the progression of the disease in humans and also requires 
lengthy studies to assess the benefits of newer treatment strategies and/or techniques.  
Currently, SPECT cardiac imaging for the detection of perfusion defects is either 
assessed qualitatively and/or semi-quantitatively. The use of tracer kinetic modelling and 
dynamic SPECT imaging is currently an active area of research and can potentially allow 
for earlier assessment of radiation-induced perfusion defects(101). Although positron 
emission tomography is not as widely available as SPECT, the implementation of 
absolute cardiac perfusion quantification is well-established. 
1.6.3.2 Cardiac PET imaging 
To the best of our knowledge, PET has not been previously used to assess perfusion 
changes following cardiac irradiation. The use of PET has advantages over SPECT due to 
its ability to provide the quantification of myocardial perfusion in absolute units of 
ml/min/g. Perfusion quantification requires quick and accurate measures of the radio-
tracer concentration within the myocardium. The temporal resolution of PET is typically 
higher in comparison to conventional SPECT systems due to better count sensitivity. 
Additionally, the temporal resolution in conventional SPECT systems are limited by the 
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need to rotate the detectors around the patient. However, newer state of the art SPECT 
systems can have temporal resolution of ~ 10s , which is similar to PET(102). In terms of 
accuracy in quantifying tracer concentration, SPECT is limited by the ability to correct 
for photon attenuation and scatter. Although SPECT attenuation and scatter correction 
techniques have been validated, they are not as well established as PET attenuation 
correction methods. Furthermore, both imaging modalities are limited by their poor 
spatial resolution. This limitation currently hinders the ability to detect non-transmural 
cardiac injury.  
Attenuation refers to the reduction in the intensity of the photons as they traverse the 
body towards the PET or SPECT detectors. To correct for this loss in intensity, the 
distance travelled by the photons and the probability of interaction across that same path, 
commonly referred to as the linear attenuation coefficients are needed. This information 
can be approximated using CT as the signal intensity in CT is known to be directly 
proportional to the linear attenuation coefficient. Estimating the attenuation path length 
travelled by the photons in PET is more straightforward than SPECT.  
In SPECT, the nuclear decay of the radio-tracer will result in a single photon emission. 
However, in PET, the nuclear decay results in the emission of a positron. Upon emission, 
the positron will become annihilated following collision with an electron. The 
annihilation of the electron and positron releases two mono-energetic photons travelling 
in directly opposite directions.  PET takes advantage of this process by monitoring the 
presence of a pair of coincidental detector events. The line traced out between two PET 
detectors sharing a coincidental event gives an approximation of the total distance 
travelled by the photons. Since these coincident events do not occur in SPECT, the 
distance travelled by the photons must be estimated through more complicated 
approaches described elsewhere (103).  Assuming these and other corrections can be 
made such that the signal is a good approximation to the tracer concentration, tracer 
kinetic modeling can be used to quantify absolute measures of myocardial perfusion. 
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1.6.3.3 Tracer kinetic modelling for myocardial perfusion 
Three main PET tracers have been utilized for myocardial perfusion quantification; 1) 
15O labelled water, 13N labelled ammonia, and 82Rubidium (104–106). Although multiple 
tracer kinetic models exist for each of these perfusion tracers; our discussion will be 
limited to the 1-compartment model for 13N labeled ammonia since this model is used 
specifically in Chapters 3 and 4 of this thesis(107).  
Several key assumptions are needed to simplify the process of estimating perfusion. The 
first and most important assumption is that the time-varying radio-tracer concentration 
within the vessel (intravascular space) and outside the vessel (extravascular 
compartment) can be measured accurately. Additionally, it is assumed that the contrast 
agent is well-mixed within these compartments such that the concentration is uniform 
throughout. Figure 1-6 shows a visual representation of the 1-compartment model used 
for the estimation of 13N-ammonia perfusion. The single compartment represents a 
volume of myocardial tissue surrounding the capillaries. 
 
Figure 1-6: Visual representation of the one-compartment model. K1 represents the 
rate of tracer accumulation within the extravascular compartment, measured in 
units of ml/min/g. The rate at which the tracer washes out of the compartment is 
defined as K2, measured in units of min-1. 
The rate of tracer accumulation within the extravascular compartment is defined as K1, 
measured in units of ml/min/g. The rate at which the tracer washes out of the 
compartment is defined as K2, measured in units of min
-1. The rate of change of tracer 
concentration within this compartment is described by the following differential equation: 
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 𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)
𝑑𝑡
= 𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) − 𝐾2𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) 
(1-1) 
where Ctissue, Cblood, and ρ represent the radio-tracer concentration in the tissue 
(extravascular compartment), concentration in the blood (intravascular space), and the 
tissue density respectively. A worked solution to equation 1-1 is provided in Appendix B. 
The quantities Ctissue and Cblood, are measured; the quantities K1 and K2 are fitted 
parameters typically obtained from a least-squares regression algorithm. The quantities 
Ctissue and Cblood are obtained from calculating the mean pixel intensities within regions of 
interest in the myocardial tissue and left-ventricular cavity (see Figure 1-7).  If the 
percentage of tracer removed from the blood to the tissue is known, commonly referred 
to as the extraction fraction; the perfusion can then be calculated from K1 using equation 
2 as originally described by Renkin and Crone (108, 109): 
 𝐾1 = 𝐸 ∗ 𝐹 (1-2) 
where, E and F represent the tracer extraction fraction and perfusion respectively.  
Although PET and SPECT can target many specific patho-physiological processes, 
myocardial SPECT perfusion has been the most interrogated sub-clinical end-point in 
radiation induced cardiac toxicity studies. Other sub-clinical end-points have been 
observed in mice following cardiac irradiation such as an increase in pro-inflammatory 
cell signals(51, 52). Cardiac inflammation can be imaged using PET in humans and may 
potentially be a novel sub-clinical marker of radiation-induced cardiac toxicity(110, 111). 
1.6.3.4 Cardiac PET imaging of myocardial inflammation 
The utility of cardiac PET for imaging the progression of myocardial inflammation 
following cardiac irradiation is a major component of the third and fourth chapters of this 
thesis. Here we provide a brief summary of this advanced imaging technique.  
Cardiac inflammation can be imaged using a very common PET radio-tracer, 
fluorodeoxyglucose (18F-FDG). 18F-FDG is a glucose analog that enters cells in 
proportion to the rate of glucose metabolism and is trapped in proportion to the rate of 
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glucose phosphoralation. Many different cells within the body, such as inflammatory 
cells and cardiomyocytes regularly metabolize glucose. Since glucose uptake is present in 
both inflammatory cells and cardiomyocytes, distinguishing these two tissues is not 
possible with 18F-FDG unless glucose metabolism can be suppressed in one cell type and 
not the other. 
 
Figure 1-7: Dynamic 13N-ammonia PET perfusion images that have been overlaid 
on cardiac MRI for anatomical context. The standard uptake value (SUV) of 13N-
ammonia is quantified in regions of interest within the myocardial left ventricular 
tissue and blood indicated by purple and yellow rings respectively.  These regions of 
interest act as measured surrogates for the radio-tracer concentration in the tissue 
(extravascular compartment) and the concentration in the blood (intravascular 
space) used in the 1-compartment kinetic model. 
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Unlike inflammatory cells, normal cardiomyocytes favour fatty acid metabolism. Taking 
advantage of the heart’s preferred utilization of free fatty acids allows us to suppress 
normal 18F-FDG uptake by cardiomyocytes. This is achieved through fasting (12-18 
hours) followed by lipid administration (via fatty diet or lipid injection) prior to PET 
imaging (110, 112). Prolonged fasting is used to lower blood insulin and blood glucose 
levels, causing the heart to switch to fatty acid metabolism. The administration of lipids 
prior to PET imaging is to provide the “starved” heart with sufficient metabolites to 
further minimize the heart’s need for glucose and consequently minimizing the uptake of 
18F-FDG. Under these conditions, observed 18F-FDG uptake in the region of the heart is 
thought to be related to the metabolism of inflammatory cells and not the 
cardiomyocytes. Figure 1-8 shows an 18F-FDG cardiac PET image of the same subject 
with and without myocardial glucose suppression. Adequate glucose suppression is not 
always achieved. The results from previous randomized trial indicated that under an 
optimized protocol suppression can be expected in ~88% of healthy human patients(113).          
This approach has been previously used to assess cardiac inflammation associated with 
non-radiation induced cardiomyopathies such as post myocardial infarction (111) and 
cardiac sarcoidosis (110). 18F-FDG PET has been previously used as a non-invasive 
means to study RIHD after stereotactic lung (114) and esophageal (115, 116) 
radiotherapy. However, to the best of our knowledge cardiac PET inflammation imaging 
has not been previously utilized to assess the progression of inflammation related to 
radiation-induced cardiac toxicity using doses relevant to the breast cancer population. 
1.6.4 Magnetic resonance imaging (MRI) 
The technological advancements in the last 10-15 years have placed MRI at the forefront 
of cardiac imaging. Cardiac MRI has a myriad of capabilities such as imaging of 
myocardial edema, coronary stenosis, myocardial perfusion, fibrosis, and valvular 
disease. During a single examination, MRI can provide a comprehensive cardiac work-up 
without delivering ionizing radiation to patients, making it an excellent candidate for 
longitudinal follow-up studies. 
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Figure 1-8: Transverse and sagittal image slices of the 18F-FDG standard uptake 
value (SUV) with (upper panels) and without (lower panels) the cardiac glucose 
suppression protocol. 
MRI is used to produce images that highlight differences in the 1 or more intrinsic 
magnetic properties of different tissues within the body. In general, an image is produced 
after a sample is magnetized within a large uniform magnetic field. Once magnetization 
is complete, tissue types with differing magnetic properties cannot be distinguished from 
each other until after the next step, commonly referred to as excitation. The excitation 
step typically consists of interrogating the sample with a short radio-frequency pulse that 
temporarily “knocks” all the tissue types away from the original magnetized state. After 
the excitation is complete, the different tissue types return back to the original 
magnetized state. However, the rate of this return will vary for different tissue types with 
different magnetic properties. This return to the original magnetized state is commonly 
referred to as relaxation. Different tissue types tend to have different relaxation rates.  
This is the key physical distinction between tissues that allows MRI images to possess 
excellent soft-tissue contrast. The final step is a carefully timed read-out of signal that is 
produced during relaxation. Timing of the read-out is crucial since it is used to maximize 
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the contrast between the different tissue types prior to complete relaxation. This process 
of magnetization, excitation, relaxation, and read-out can be repeated until the desired 
image quality is achieved.  Brown et al provide a more comprehensive discussion of 
MRI(117). 
To the best of our knowledge, only a single full length article has been published where 
cardiac MRI is used for the study of radiation induced cardiac toxicity in the left-sided 
breast cancer population(118). Heggemann, et al performed cardiac MRIs of 49 left-sided 
breast cancer patients at baseline, 6 months, 12 months, and 24 months following 
adjuvant treatment. Temporary decreases in the contractile function of the heart that 
resolved 24 months post radiation were observed. No evidence of fibrosis was presented; 
fibrosis was assessed qualitatively through late gadolinium MRI contrast enhancement. 
As stated by the authors, a major limitation of their study is low patient accrual due to the 
extended duration of each imaging session. Numerous functional parameters can be 
imaged with MRI and the lack of knowledge with regards to radiation-induced cardiac 
disease makes it difficult to tailor a protocol to detect radiation induced cardiac toxicity. 
Controlled large animal studies using clinically approved MRI sequences may be 
beneficial towards the future implementation of MRI imaging protocols with an aim to 
monitor the progression of radiation induced cardiac toxicity in humans. 
For clarity, the information provided in this section is not intended to motivate the use of 
MRI in the current thesis. The capabilities of MRI for assessing cardiac function were not 
utilized in this thesis; however, future work may include an investigation of cardiac MRI 
on the same subjects to assess RIHD.  
1.6.5 Hybrid imaging techniques 
Each of the imaging modalities discussed above have their inherent strengths and 
limitations. Often times the strengths of one imaging method tends to be a weakness of 
the other and vice versa. This leads to an inevitable compromise when choosing which 
imaging modality is optimal. This problem has motivated the development of many 
hybrid imaging systems in which two modalities are combined into a single system(119). 
Arguably the most successful “marriage” between two imaging modalities was the 
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combination nuclear emission tomography (SPECT or PET) with computed tomography 
(CT). The successful combination of SPECT with CT and PET with CT has led to a 
single imaging system with the ability to provide functional information such as 
perfusion and cellular proliferation overlaid on anatomical cross-sections for context. 
Additionally, attenuation correction obtained from the CT has significantly improved 
image quality of SPECT and PET. Today virtually all commercially manufactured PET 
systems come with a CT. Due to the success of these systems the commercial 
development of rival PET-MRI and SPECT-MRI hybrid systems has emerged. Unlike 
CT which is predominately used for anatomical imaging, MRI is capable of both 
functional and anatomical imaging.  
The complementary strengths of PET and MRI are shown in Figure 1-9. In the context of 
this thesis, PET-MRI represents an attractive approach to understanding and monitoring 
the progression of radiation-induced cardiac toxicity. As previously mentioned, 
preclinical studies in mice have shown evidence of inflammation, changes in myocardial 
perfusion, and transient increases in cellular proliferation(52). In humans, typically one 
and at most two of the above functional parameters can be assessed in a single session 
using PET-CT or SPECT-CT. Unlike PET-CT and SPECT-CT, PET-MRI acquires 
images in true simultaneous fashion; therefore it has the potential to acquire more 
functional information regarding the heart in a shorter imaging session. Most of the 
hardware compatibility issues between the PET and MRI appear to have been sorted 
out(120). However, the biggest limitation of PET-MRI is with regards to attenuation 
correction for the PET images. Unlike CT, the MRI signal is not related to the linear 
attenuation coefficients of matter. For example, although bone and lung are quite 
different in terms of their ability to attenuate photons, they’re highly indistinguishable in 
the majority of MRI pulse sequences. Due to the importance of this problem, MRI 
attenuation correction has become a highly active area of research(121–123).  
A commonly used approach for attenuation correction in MRI is to segment anatomical 
areas corresponding to lung, fat, and tissue using a specialized MRI pulse sequence (124). 
This is followed by a substitution of the original pixel intensities with discrete attenuation 
coefficient values that are typically observed in lung, fat, and tissue. Validation against 
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PET-CT attenuation correction for cardiac PET-MRI imaging is supported in the 
literature(121). Although we are optimistic and excited with regards to this novel imaging 
platform, a significant amount of research is needed to understand the ultimate role of 
PET-MRI in cardio-oncology. 
 
Figure 1-9: Radar diagrams of the relative strengths and weaknesses of MRI, PET, 
and hybrid PET-MRI. This figure is adapted with permission from Shah NJ, et al. 
J. Magn. Reson. 2013;229:101–115. 
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1.7 Gaps in knowledge, challenges, questions, and 
hypotheses 
Cardiac side effects in left-sided breast cancer patients  after post-operative radiotherapy 
has become one of the most debated issues in radiation oncology (20, 125, 126). This is 
because the number of patients at risk is large and many are young. The increased rate of 
a major coronary event in breast patients is high, 1.32 relative risk of a major coronary 
event in comparison to age-matched controls (17). The relative risks are even greater in 
cohorts with pre-existing risk factors such as smoking (1.87) and diabetes (3.23) (17). 
Fortunately, approaches such as active breathing control, can reduce the mean dose to the 
heart during treatment. However, the benefits of these approaches and the means in 
which they are assessed have been recently put into question(43, 126).  The widespread 
clinical adoption of active breathing control and other similar techniques aimed at 
reducing mean heart doses during radiotherapy are directly impacted by the following 
problems/challenges. 
1. Guidelines for radiotherapy planning left-sided breast cancer are needed to 
minimize the risk of radiation-induced cardiac toxicity. Currently, such a 
guideline does not exist since the true relationship between cardiac dose and 
cardiac toxicity remains uncertain. The risk of a major coronary event is often 
cited to increase by 7.4% per Gy to the heart (17). However, due to inherent 
difficulties in estimating the dose to the heart, the uncertainty in this value is 
likely even higher than what is reported (95 % confidence interval, 2.9% to 
14.5%). Thus, further work is needed to provide more accurate assessment of 
dose to the heart and sub-structures such as the coronary arteries.     
2. Since cardiac toxicity following breast radiotherapy is a latent side-effect of 
treatment (~10-15 years post treatment), recently proposed strategies to mitigate 
this effect cannot be assessed in a timely manner with current approaches.      
The following questions have been formulated with the aim of helping to guide decisions 
with regards to radiotherapy planning and delivery that can minimize radiation-induced 
cardiac toxicity: 
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1. Does respiratory motion impact left-side breast cancer radiotherapy planning in 
terms of the accuracy of estimating doses to the heart, left-ventricle, and LAD? 
2. Can the effects of heart, left ventricular, and LAD irradiation on myocardial 
perfusion and inflammation be visualized using PET at radiation dose levels 
comparable to modern left-sided breast radiotherapy?  
3. Can the effects of cardiac irradiation be visualized using PET at earlier time 
points in comparison to other previously used imaging modalities? 
4. Is there a spatial relationship between the magnitude of dose and regional changes 
in cardiac inflammation? 
5. Is there a spatial relationship between the magnitude of dose and regional changes 
in cardiac perfusion? 
6. Are specific regions within the heart such as the arteries more sensitive to 
radiation effects than others?   
The answers to the above questions will be instrumental in the design of future clinical 
studies looking to properly assess strategies for mitigating radiation induced cardiac 
toxicity following radiotherapy. Lastly, we present two hypotheses: 1) regarding radiation 
treatment planning of left-sided breast cancer and 2) regarding the assessment cardiac 
responses to radiation treatment: 
A significant variation in dose across heart structures is attributable to respiratory-
induced motion during left-breast cancer radiotherapy.  
A reduction in left ventricular perfusion and an enhancement in inflammation is related 
to local radiation dose levels within the heart. 
1.8 Thesis outline 
1.8.1 Radiation dose uncertainty associated with motion of the 
heart, left ventricle, and left anterior descending artery during 
left-sided breast radiotherapy (Chapter 2) 
The second chapter of this thesis is adapted from an original research article, 
“Assessment of Intrafraction Breathing Motion on Left Anterior Descending Artery Dose 
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During Left-Sided Breast Radiation Therapy” published in the International Journal of 
Radiation Oncology*Biology*Physics 2016 (in press; published online: February 12, 
2016) by El-Sherif O, Yu E, Xhaferllari I, Gaede S.   
In this chapter doses to heart, left ventricle, and LAD were calculated for 30 left-sided 
breast cancer patients receiving radiation therapy.  Radiation dose was calculated using 
the clinical standard free breathing CT scans that do not account for respiratory motion 
and was compared to calculations where respiratory motion was accounted for. The 
impact of respiratory motion on heart dose was assessed through 4D-CT imaging and 4D 
dose accumulation. The findings show that the clinical standard is appropriate for 
measuring doses to the heart and left ventricle; however, a clinically significant 
discrepancy exists for the LAD. Preclinical studies have suggested that the dose to the 
artery may be of equal or greater concern than the dose to the heart. Thus, the results 
from this study will aid future studies that aim to correlate artery dose to radiation-
induced cardiac toxicity. Additionally, to the best of our knowledge this is the largest left-
sided breast cancer patient study assessing dose to the heart, left ventricle, and LAD that 
uses both modern day radiotherapy techniques and accounts for respiratory motion. 
Results from this study are used in Chapters 3 and Chapter 4 to aid in the design of a 
canine model of cardiac exposures from left-sided breast radiotherapy. 
1.8.2 Early 18F-FDG and 13N-ammonia cardiac PET imaging in a 
canine model following cardiac exposures associated with 
breast cancer radiotherapy (Chapter 3) 
The third chapter of this thesis is adapted from another original research article, “18F-
FDG and 13N-ammonia Cardiac PET Imaging in a canine model of cardiac exposures 
associated with breast cancer radiotherapy”, by El-Sherif O, Xhaferllari I, Sykes J, Butler 
J, DeKemp R, Renaud J, Battista J, Wisenberg G, Prato F.S., Gaede S.  The article has 
been accepted pending revisions from Radiotherapy & Oncology.  
In this chapter a canine model of cardiac exposures associated with left-sided breast 
cancer radiotherapy is presented.  The hearts of five canines were imaged using 18F-FDG 
(inflammation tracer) and 13N-ammonia (perfusion tracer) cardiac PET at baseline, 1 
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week, and 4 weeks following cardiac irradiation. The delivered dose to the heart, left 
ventricle, and LAD was designed to match the expected biological equivalent dose from a 
multi-fractionated left sided breast cancer population (data obtained from Chapter 1). The 
distribution of the dose was intentionally focused on the LAD and anterior apical portion 
of the left ventricle. This resulted in a dose-gradient within the heart. Although this 
specific dose gradient is not typically observed in patients, it allowed us to assess the 
relationship between spatial dose deposition and cardiac injury. The results from this 
study showed that cardiac PET can identify statistically significant increases in the uptake 
of 18F-FDG and 13N-ammonia, as early as 1 week following cardiac irradiation. A spatial 
relationship between dose and tracer uptake was not observed;  rather the response to 
radiation was global, affecting regions with higher dose in comparison to regions 
irradiated at a substantially lower dose similarly.  
These novel findings suggest that an increase in myocardial perfusion (beginning ~1 
week post irradiation) occurs and is associated with a global inflammatory response 
(increased FDG uptake). Further work is needed to establish a more concrete connection 
between these early changes observed using cardiac PET with long-term cardiac toxicity.  
1.8.3 The utility of 18F-FDG and 13N-ammonia PET for monitoring 
the progression of cardiac inflammation and perfusion 
following focused cardiac irradiation in canines (Chapter 4) 
The fourth chapter of this thesis is a longitudinal follow-up of the same five subjects from 
chapter 3. The aim of this study is to identify whether the changes observed in 
myocardial perfusion and inflammation observed in chapter 3 are acute responses to 
radiation or persistent.  Here, the hearts of five canines were imaged using 18F-FDG 
(inflammation tracer) and 13N-ammonia (perfusion tracer) cardiac PET at 3 months, 6 
months, and 12 months following cardiac irradiation.  
The results of this study show that 18F-FDG and 13N-ammonia PET can be used for the 
longitudinal assessment of myocardial perfusion and inflammation in association with 
cardiac external beam irradiation. In response to cardiac irradiation, progressive increases 
in FDG uptake, a non-invasive means of assessing inflammation were observed and 
36 
 
 
 
supported by preliminary ex-vivo histology. A transient increase in myocardial perfusion 
that returned to baseline levels (in 3 subjects) and below baseline levels (in 2 subjects) 
was also observed. A global response to radiation was observed affecting regions with 
high dose and low doses similarly;   further validation of this finding through more 
complete histology is needed. These results provide support for the future use of 18F-FDG 
and 13N-ammonia PET imaging for the longitudinal assessment of previously proposed 
treatment options aimed at reducing radiation induced cardiac toxicity in humans.    
This study is expected to be submitted for publication in Radiotherapy & Oncology 
pending a more comprehensive histological analysis of the ex-vivo cardiac samples. The 
histology is currently underway. 
1.8.4 Conclusions and Future Work (Chapter 5) 
Here, the key findings from the previous chapters are summarized and potential future 
related studies are proposed and motivated. 
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Chapter 2  
2 Radiation dose uncertainty associated with motion of 
the heart, left ventricle, and left anterior descending 
artery during left-sided breast radiation therapy 
Postoperative radiotherapy (RT) is the standard of care for breast cancer patients. 
Technological advances in medical imaging and RT have led to significant improvement 
in the survival rate of these patients (127). However, a portion of breast cancer survivors 
are now exhibiting the latent effects of normal tissue irradiation, namely, radiation-
induced ischemic heart disease (RIHD)(125). Due to proximity, left-sided breast cancer 
(BREL) patients’ hearts are partially irradiated during RT, placing them at a greater risk 
of RIHD(17, 32, 128). 
Tangential intensity modulated radiation therapy (IMRT)(129–131) delivered under free-
breathing is widely used for cardiac dose-sparing(132, 133).Recently, motion-
management techniques such as, active breathing control (ABC), deep inspiration breath-
hold (DIBH), and inspiratory-gating (IG) have been proposed as options for reducing 
incidental cardiac irradiation(134). Although numerous studies have shown that these 
motion-management techniques can significantly reduce the dose to the heart, the clinical 
benefits are still unknown. In a randomized trial, Zellars et al showed that the use of ABC 
was not significantly associated with the prevention of cardiac perfusion deficits (43). 
Preclinical studies suggest that the radio-sensitivity of the heart is heterogeneous and that 
direct radiation exposure to specific regions within the heart, specifically, the major 
coronary arteries are correlated with the acceleration of the atherosclerotic process(33, 
48, 49). In light of these preclinical findings, the typically reported dose estimates for just 
the heart volume alone may not be sufficient for assessing the efficacy of cardiac dose 
sparing techniques. Doses to the heart may need to be supplemented with dose estimates 
for the coronary arteries as well. Unfortunately, due to the impact of respiratory motion, 
estimating the dose to the coronaries is difficult. Additionally, the standard of care for 
left-sided breast RT uses a standard fast helical CT (FH-CT) for treatment planning that 
does not account for internal organ motion during treatment simulation.   
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To address this concern, the dosimetric impact of patient breathing on heart dose has 
been previously quantified through the use of 4D-CT (83, 84, 87, 88).  However, these 
studies have not investigated the dosimetric impact on the cardiac sub-structures such as 
the left ventricle (LV) and the left anterior descending artery (LAD). To better understand 
the limitations of using standard FH-CT for left breast RT planning we have compared 
DVH metrics for the heart, LV, and LAD regions obtained from the FH-CT to a 4D dose 
accumulation. 
The purpose of this study is to use 4D-CT imaging to predict the level of uncertainty in 
cardiac dose estimates of the heart and its sub-structures that arises due to breathing 
motion during RT. Additionally, the impact of potential errors associated with dose 
deformation on the 4D dose accumulation within the heart, LV, and LAD is examined. 
2.1 Methods and Material 
2.1.1 Imaging 
Institutional review-board approval was obtained to retrospectively analyse the planning 
CT data of 30 consecutive patients whom have previously undergone RT for left-sided 
breast cancer. The study design is outlined in Figure 2-1. As standard of care within our 
institution, all BREL patients receive both a standard fast-helical CT (FH-CT) and a 4D-
CT for RT planning. The FH-CT and 4D-CT were acquired using a 16-slice Philips 
Brilliance large bore CT scanner (Philip Medical Systems, Milpitas, CA). The Varian 
RPM system (Varian Medical Systems, Palo Alto, CA) was used to monitor the motion 
of an external fiducial positioned on the patient during 4D-CT imaging. The fiducial 
provides a surrogate for the internal organ motion during normal respiration and is used 
to sort the 4D-CT data into 10 separate breathing phases. 
2.1.2 Treatment planning 
Treatment plans were created on the FH-CT using the Pinnacle3 treatment planning 
system (Philips Radiation Oncology Systems, Fitchburg, WI). Dose calculations were 
performed with the collapse cone convolution algorithm and tissue inhomogeniety 
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correction implemented in Pinnacle3.A Summary of the patient treatment characteristics 
for this study can be found 
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Appendix B: Worked general solution to equation 1-1 
 
 𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)
𝑑𝑡
= 𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) −  𝐾2𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) 1-1 
begin by taking the Laplace transform of both sides of equation 1-1 
 𝐿 {
𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)
𝑑𝑡
} = 𝐿{𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) − 𝐾2𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)} 
 
in the Laplace domain we have the following equation 
 𝑠𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) − 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(0) = 𝜌𝐾1𝐶?̅?𝑙𝑜𝑜𝑑(𝑡) −  𝐾2𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) A-1 
where 𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) 𝑎𝑛𝑑 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(0) are the Laplace transform of 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 and the initial 
condition in the time domain respectively. Since the initial condition is equal to zero we 
can rearrange equation A-1 to solve for  𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) 
 𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) =
𝜌𝐾1?̅?𝑏𝑙𝑜𝑜𝑑(𝑡)
𝑠+ 𝑘2
  
 
𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) = 𝜌𝐾1𝐶?̅?𝑙𝑜𝑜𝑑(𝑡)
1
𝑠 + 𝑘2
 
 
The following equation is obtained by taking the inverse Laplace transform of both 
sides. Also, recall that multiplication in the Laplace domain is convolution in the time 
domain. 
 𝐿−1𝐶𝑡𝑖𝑠𝑠𝑢𝑒𝑡=𝐿−1𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑𝑡⊗𝐿−11𝑠+ 𝑘2  
 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) = 𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) ⊗  𝑒﷩ −  𝐾2𝑡  
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Appendix C 
. 
 
 Figure 2-1: Outline of study design. Abbrev: LV= 
left ventricle; LAD = left anterior descending artery. 
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2.1.3 4D dose accumulation 
When performing the 4D-dose accumulation, each phase of the 4D-CT was weighted 
equally. Due to patient variability in breathing, time-weighted dose accumulations may 
be necessary, specifically when the 4D-CT is reconstructed in amplitude mode (135). 
However, when a 4D-CT is reconstructed in phase mode,  the equally weighted approach 
has some inherent probability-weighting (135). This can be observed by examining the 
position of the heart in the 40 -70% phases. The 40-70% phases all tend to be close to the 
end of exhalation from an amplitude perspective (see Figure 2-2). To obtain the 
accumulated dose distribution, the FH-CT was registered to the 4D-CT then the finalized 
FH-CT treatment fields and isocenter were transferred to each phase of the 4D-CT. An 
automatic rigid registration was performed between the FH-CT and 4D-CT minimizing 
the squared differences of the voxel intensities. The quality of the registration between 
the FH-CT and 4D-CT phase were verified qualitatively by visually comparing the 
alignment of the vertebral bodies. The dose was recalculated on each of the phases. The 
DICOM RT dose files were then exported from Pinnacle to MIMVista (MIM Software 
Inc., Cleveland, OH, version 6.4.3) to obtain the deformable dose accumulation. The 
warped doses were accumulated to the 50% phase of the 4D-CT for all patients, the heart, 
LV, and LAD contours on the 50% phase of the 4D-CT were the ones used in our 
comparison with the FH-CT. 
 
Figure 2-2: A) Respiratory trace of a representative patient. The 5 coloured boxes 
outline the amplitude divisions of the RPM trace corresponding to the end of 
exhalation (EOE), end of inhalation (EOI), preEOE, preEOI, and mid ventilation 
(midVENT) respiratory amplitudes. (B) The corresponding RPM derived frequency 
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distribution for each respiratory phase. (C) Amplitude of the craniocaudal centroid 
position of the heart contour for each 4D-CT phase of a representative patient. 
2.1.4 Contouring and dose warping accuracy 
To improve the accuracy of our contours, we employed a previously validated cardiac 
atlas(136). Contours were originally drawn on the FH-CT then propagated to all 10 
phases of the 4D-CT through the deformation algorithm within MIMVista (137). Auto-
propagated contours were reviewed and edited for any delineation errors. Additionally, to 
account for dose uncertainty to the LAD due to cardiac motion, all LAD contours were 
created with a standard 5mm diameter (58). 
The mean spatial error of the deformation algorithm has been previously estimated to be 
1.5mm(137–139). The sensitivity of the DVH metrics due to the uncertainty in the dose 
deformation is estimated through rigid translation of the contours in three directions. All 
contours associated with the dose accumulation were shifted in the anterior-posterior and 
lateral-medial directions by ±0.75mm, ±1.5mm, ±3.5mm, and ±7.0mm. These shift 
values are in line with previously reported deformation errors associated with MIMVista 
(137–139). It should be noted that the max reported error can be up to 20mm, however, a 
conservative max of 7 mm is considered here with the following justification; Nie et al 
showed that in the presence of added image noise,<4% of the total voxels can be 
expected to have deformation errors >7 mm and the max reported error of 20mm are 
present in less than 1% of the volume (140). Additionally, the 20 mm error may not be 
relevant here considering this value exceeds the magnitude of total respiratory induced 
heart motion. Due to the slice thickness being 3mm, superior-inferior translations of 
±3.5mm and ±7.0mm were only performed. Variation in dose due to translation is 
inevitable even without dose warping since many of these contours are in close proximity 
to high spatial dose gradients. Thus the FH-CT contours were translated along the un-
warped dose distribution for comparison. Dose variation is reported in all three directions 
as the dose difference (mean ± standard error of mean) between the translated contours 
and the original fixed contours. A paired samples t-test was used to compare means from 
the shifted 4DCT contours on the warped dose distribution to the shifted FH-CT contours 
on the un-warped dose.  
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2.1.5 Statistics and data analysis 
Student’s paired t-test (p values< 0.05 were considered statistically significant) and 
Bland Altman plots were used to assess the level of agreement between FH-CT and 4D 
dose accumulation(141). As suggested by Bland et al, the 95% confidence interval of the 
difference in the measures is used to illustrate how far apart the dose estimates from 4D 
dose accumulation and FH-CT are likely to be for most patients. Prior to checking for 
statistical significance, Shapiro-Wilk tests were performed to verify the normality 
assumption required by the t-test. 
2.2 Results 
2.2.1 Delineation errors associated with auto-propagation 
All contours were manually contoured on the FH-CT with guidance from a validated 
cardiac atlas(136).  Auto-propagation of these contours from the FH-CT to the 4D-CT 
required some minor manual editing for the LAD contour only, the heart and LV 
contours did not have any obvious delineation errors. The auto-propagation produced the 
following 2 errors with the LAD contour; 1) shrinking of the LAD contour and 2) 
splitting of the LAD contour into 2 separate ROIs within the same slice. Shrinking of the 
LAD contour is problematic due to the spatial uncertainty of the LAD caused by cardiac 
motion (58). These errors were addressed as follows; the LAD contours were expanded to 
ensure a standard 5mm margin. Split LAD contours were qualitatively judged based on 
which of the two contours were closest to the expected anatomical position of the LAD. 
The LAD typically originates from the left main artery and then runs down the 
interventricular groove, between the left and right ventricles. The contour closest in 
proximity to this definition is kept and the other is deleted. 
2.2.2 Dosimetric comparisons 
The irradiated volume of the heart and LV typically exhibited minimal differences when 
comparing the FH-CT to each phase of the 4D-CT. However, larger differences in 
irradiated volume were observed in the estimated dose to the LAD region. The LAD 
region’s potential sensitivity to motion can be visualized in Figure 2-3. The LAD is 
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typically situated in close proximity to the steep dose-gradients along the beam edges of 
the tangential fields.  
 
Figure 2-3: A comparison of the fast helical CT (FH-CT), end of exhalation, and end 
of inspiration radiation dose distributions for a representative patient. The heart, 
left ventricle (LV), and left anterior descending artery (LAD) are outlined in 
magenta, yellow, and red respectively. Differences in the irradiated volume and 
magnitude of the heart, LV, and LAD are outlined by the white arrows for 
comparison. 
Figure 2-4 shows differences between EOI, EOE, and the 4D accumulated DVHs of the 
heart, LV, and LAD for a representative patient. The comparison of the mean dose 
difference between FH-CT and 4D accumulated doses for all patients is shown in Figure 
2-5. Overall the dose differences were generally minimal for the heart and LV. The 
average ± 95% confidence interval of 4D accumulated dose and FH-CT differences in 
mean dose estimates for the heart, LV, and LAD were 0.1 ± 0.5 Gy, 0.0 ± 1.0 Gy, and -
0.5 ± 8.7 Gy respectively.  The average ± 95% confidence interval of 4D accumulated 
dose and FH-CT differences in V50% for the heart and LV were 0.8 ± 1 % and 1.0 ± 3% 
respectively. The FH-CT appears to underestimate for the maximal dose to 0.2 cc of the 
LAD in comparison to the 4D accumulated dose by 1.3Gy ± 4.4Gy (mean ± SD). The 
uncertainty in the dose accumulation due to errors in deformation was assessed by 
comparing dose estimates after a rigid translation of the contours in three directions. 
Additionally, the spread of the warped dose can be interpreted as the uncertainty in the 
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mean heart, LV, and LAD dose metrics. The results of this analysis are presented in 
Table 2-1. Shifting of the heart and LV contours in the medial-lateral and anterior-
posterior directions on the warped 4D dose did not result in any statistically significant 
differences in comparison to the same contour shifts on the un-warped FHCT dose. 
Superior-inferior shifts of the heart contour resulted in a significant difference, however, 
the magnitude of this difference is small (warped dose: 0.30Gy ± 0.03; un-warped dose: 
0.33Gy ± 0.03 for a 7mm shift).Similarly, 7mm superior-inferior shifts of the LV had 
statistically significant but likely clinically insignificant differences (warped dose: 
0.45Gy ± 0.05; un-warped dose: 0.50Gy ± 0.06) since they are within the patient setup 
uncertainty of the treatment. For the LAD, medial-lateral, anterior-posterior, and 
superior-inferior shifts on the warped dose were statistically different from the shifts on 
the un-warped dose. The largest difference was observed for the medial-lateral shifts of 
7mm (warped dose: 4.36Gy ± 0.37; un-warped dose: 4.98Gy ± 0.40). 
2.3 Discussion and conclusions 
The results of our study show that the mean dose to the heart and LV exhibit small to 
moderate variations across a typical BREL patient’s breathing cycle, typically less than ± 
0.5 Gy for the mean heart dose and  ± 1.0 Gy for the mean LV dose. However, no 
significant bias was observed between the 4D-CT and FH-CT derived cardiac DVH 
metrics. This finding is in agreement with several previous publications that also used 
4D-CT for the assessment (83, 84, 87, 88). The variation in mean heart dose due to 
intrafraction motion (movement during imaging/treatment) shown here is on the same 
order of magnitude as previously reported errors expected due to potential organ 
delineation inaccuracies, 0.14±0.14 Gy (136).  Similar to the heart, the errors due to 
intrafraction motion of the LV appear to be only slightly larger than inaccuracies due to 
delineation, ±1.0 Gy vs  ±0.3Gy for the LV (136).The heart and LV are relatively large 
volumes and typically only a small proportion of these volumes are within the region of 
the dose distribution where the dose-gradient is steep. Thus, movements of the heart and 
LV in the medial-lateral or superior–inferior directions cause minor variations in the 
overall mean dose estimates to these structures. However, the heart is an organ composed 
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of many different tissues that are integral to maintaining functionality. To date, the 
variation in radio-sensitivity of the various tissues within the heart is poorly understood.  
 
.  
Figure 2-4: Variation between the end of inspiration (EOI), end of exhalation 
(EOE), and 4D dose accumulation (4D) dose volume histograms (DVH) of a 
representative patient. Variation in dose to the heart, left ventricle (LV), and left 
anterior descending artery (LAD). (B) is an inset of (A). 
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Figure 2-5: Bland Altman plots showing the level of agreement between the 4D dose 
accumulation 4D-dose and the fast helical CT (FH-CT) mean dose estimates for the 
heart (A), left ventricle (B), and LAD (C). The blue and red lines indicate the mean 
difference and 95% confidence interval respectively for all 30 patients. 
Table 2-1: differences in mean dose between shifted and un-shifted contours on 
warped and unwarped dose distributions 
 Planned Medial-Lateral Shift Anterior –Posterior Shift Superior – Inferior Shift 
 Dose warped unwarped P warped unwarped p warped unwarped p 
Heart 2.34±0.06          
 ±0.75 mm 0.11±0.01 0.11±0.01 0.80 0.15±0.01 0.15±0.01 0.81 -- -- -- 
 ±1.50 mm 0.20±0.02 0.20±0.02 0.97 0.26±0.03 0.26±0.02 0.46 -- -- -- 
 ±3.50mm 0.42±0.03 0.42±0.03 0.85 0.55±0.05 0.54±0.05 0.28 0.15±0.02 0.16±0.02 0.04 
 ±7.00mm 0.82±0.06 0.82±0.06 0.96 1.07±0.10 1.05±0.10 0.16 0.30±0.03 0.33±0.03 <0.01 
LV 3.19±0.19 
         
 ±0.75mm 0.16±0.02 0.16±0.02 0.86 0.21±0.02 0.21±0.02 0.80 -- -- -- 
 ±1.50mm 0.28±0.03 0.29±0.03 0.73 0.37±0.04 0.37±0.04 0.95 -- -- -- 
 ±3.50mm 0.60±0.06 0.60±0.06 0.56 0.78±0.09 0.79±0.09 0.89 0.23±0.03 0.25±0.03 0.16 
 ±7.00mm 1.16±0.11 1.18±0.11 0.54 1.53±0.16 1.54±0.17 0.86 0.45±0.05 0.50±0.06 0.02 
LAD 11.93±0.63 
         
 ±0.75mm 0.61±0.05 0.70±0.05 0.02 0.85±0.07 0.91±0.07 0.19 -- -- -- 
 ±1.50mm 1.09±0.09 1.22±0.09 0.02 1.52±0.13 1.62±0.12 0.24 -- -- -- 
 ±3.5mm 2.29±0.19 2.60±0.20 0.01 3.17±0.27 3.42±0.27 0.13 0.80±0.08 1.99±0.09 <0.01 
 ±7.00mm 4.36±0.37 4.98±0.40 <0.01 5.90±0.53 6.49±0.55 0.04 1.63±0.16 2.00±0.16 <0.01 
Tabulated values represent the differences in mean dose between shifted and un-shifted contours (mean ± standard error of mean).  Dose differences 
are reported in absolute units of Gy. Boldfaced values indicate statistically significant differences between shifts on warped doses vs shifts on un-warped 
doses (p<0.05)  
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What is known is that the function of arteries and microvasculature within the heart can 
be compromised through radiation exposure(33). Our use of 4D-CT and 4D-dose 
accumulation have shown that incorporating the movement of the heart provides added 
information with regards to the blurring of the dose during radiotherapy. Additionally, we 
have shown that the area of the heart that may be of most concern, is the LAD, however, 
further validation in clinical studies is still needed to better understand the relationship 
between LAD irradiation and RIHD. The use of 4D-CT in potential future work in this 
area is suggested to obtain more accurate dose estimates to the LAD. 
The irradiated volume of the LAD was shown to have a much greater variation due to 
respiratory induced motion than both the heart and LV; ± 8.7 Gy for the mean LAD dose.  
To the best of our knowledge this is the first time the impact of intrafraction motion on 
LAD dose has been reported. A previous study examined the displacement of the LAD 
and showed the respiratory induced motion can lead to displacements as large as 9mm 
towards the chest wall(84). These reported LAD displacements  are consistent with what 
was observed in this study. The visibility of the LAD on both FH-CT and 4D-CT is 
difficult and the accuracy of the contour without the use of IV contrast is a limitation for 
this study. However, this study shows that errors due to intrafraction motion of the LAD 
appear to be larger for patients than the uncertainty that arises due to contouring 
inaccuracies, ± 8.7 Gy vs 2.56Gy(136).  
Another source of uncertainty comes from the dose deformation algorithm. However, the 
95% confidence intervals for the errors associated with the intrafraction breathing motion 
of the LAD appear to exceed the errors associated with dose deformation. Dose 
deformation uncertainty was assessed here using rigid translations of the contours (Table 
2-1).The small differences observed between the warped plan and the unwarped plans 
suggest good agreement between the local dose gradient magnitudes. Shifting the LAD 
contour by the mean expected error of the deformation algorithm (1.5mm)resulted in an 
uncertainty in the LAD dose of ~1.5 Gy, less than the variation observed due to 
intrafraction breathing motion (± 8.7 Gy). The 7mm shifts representing a “conservative 
max” error of the deformation algorithm resulted in large variations in the estimated LAD 
dose (5.9 Gy). Previous studies have reported <4% of the total voxels to have 
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deformation errors of this magnitude(140).Thus, although the likelihood of a 7mm error 
in deformation appears to be small, inaccuracies in the dose deformation of this 
magnitude will have a significant impact on reported dose estimates to the LAD. A 
limitation of this analysis is that the total uncertainty due to deformation is difficult to 
quantify for small structures in close proximity to high dose gradients such as the LAD. 
Further investigation of the uncertainty in the dose accumulation for this patient cohort is 
still warranted. 
The concern for dose deposition to the LAD for BREL patients is substantiated by the 
proportion of these patients presenting with clinically significant coronary stenosis of the 
LAD and myocardial perfusion defects that are isolated to myocardial segments known to 
be supplied by the LAD (18, 59, 142, 143).  
This study assumes that the respiratory trace of the external surrogate during 4D-CT 
simulation is reproducible during RT. Although, patient breathing likely varies from day 
to day, a previous study reported good day to day reproducibility of probability 
distributions for lung tumour motion(144). We expect similar reproducibility considering 
the respiratory induced motion of the heart is more subtle than that of a lung tumour.  
Although the 4D-CT may provide added information with regards to the motion of the 
internal anatomy, there is an added risk of radiation-induced malignancies due to the 
increased dose from the 4D-CT. The effective dose from 4D-CT is approximately 8 times 
the dose from a conventional FH-CT(145) (~6mSv vs ~48mSv).The lifetime attributable 
risk (LAR) for fatal cancer induction was estimated in adults to be 33 cases per 100,000 
standard chest CT examinations (~0.03%)(146). An approximated LAR from a 4D-CT 
can be expected to yield 231 more cases per 100,000 (~0.2%). Studies have shown that a 
reduction in heart dose by 1Gy correlates to a 7.4% decrease in the rate of a major 
coronary event(17). The 0.2% increased LAR for the induction of a fatal cancer due to 
the added exposure from 4D-CT can be potentially outweighed by just a small reduction 
in the heart dose (~0.03Gy to avoid a coronary event or ~1.2 Gy to avoid death due to 
heart disease). Thus, prior to the adoption of 4D-CT for left-sided breast treatment 
planning, further work is needed to identify if the added information from the 4D-CT can 
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be successfully used in the treatment planning process to reduce the dose to the heart, 
LV, and/or LAD.  
In conclusion, we found small variations in the dose to heart and LV due to intrafraction 
respiratory motion during RT. However, the LAD showed substantial variation in dose 
due to breathing. Although the respiratory induced variations in LAD dose may not have 
an immediate clinical impact, we suggest that future clinical studies looking at the 
relationship between RIHD and LAD dose to consider the use of 4D dose accumulation 
rather than relying on the static treatment planning methods of the past.  
 
54 
 
 
 
Chapter 3  
3 Early 18F-FDG and 13N-ammonia PET imaging in a 
canine model following cardiac exposures associated 
with breast cancer radiotherapy 
Chapter 3 hypothesis: A reduction in left ventricular perfusion and an enhancement in 
inflammation is related to local radiation dose levels within the heart. 
Advances in imaging and radiotherapy have led to significant improvement in the 
survival rate of breast cancer patients(127). However, several recent studies have shown 
that a large proportion of breast cancer patients show evidence of late radiation induced 
ischemic heart disease (RIHD)(16, 17, 147) following tangential external beam 
radiotherapy. Due to the development of new techniques many patients are living longer.   
Previously latent effects of radiation are now being seen. The relative risk of ischemic 
heart disease is believed to be proportional to the volume of the heart that is irradiated 
during therapy(17). To address this concern, some cancer clinics are now using 
respiratory motion management techniques, such as deep inspiration breath-holding 
(DIBH), to add greater spatial separation between the heart and the left-breast during 
radiotherapy(148, 149). The use of DIBH has been shown to reduce the irradiated volume 
of the heart. Unfortunately, due to the close proximity of the heart to the left breast, the 
DIBH technique cannot completely eliminate the incidental cardiac irradiation associated 
with radiotherapy. Reported average doses to the myocardium and the left anterior 
descending artery (LAD) in patients treated with DIBH can be up to 2Gy and 8Gy, 
respectively(148). Cancer centers using tangential fields that have not adopted the DIBH 
technique can see average doses as high as 6 Gy and 32 Gy to the myocardium and LAD, 
respectively. It is believed that the relative risk of a major coronary event increases by 
7.4% per Gy without any evidence of a threshold dose below which there is no added 
risk(17).The pathogenesis of RICD is not well understood and clinical symptoms do not 
typically manifest until 10-15 years after radiotherapy. However, a recent study in mice 
identified significant up-regulation of inflammatory markers expressed on the vascular 
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endothelium in response to radiation(52),  suggesting changes in the microvasculature 
developing as early as 10 and up to 20 weeks post-irradiation. 
18F-FDG PET has been previously used as a non-invasive means to study RICD after 
stereotactic lung(114) and esophageal(115, 116) radiotherapy. Mean doses to the heart 
after lung and esophageal cancer are typically greater than 20 Gy, higher than what is 
observed in breast cancer patients. As previously described in Chapter 1, the cardiac 
injuries observed at high doses (i.e. pericarditis) are different from those observed at 
lower doses (i.e. ischemia). Due to this difference in the expected radiation induced 
injury to the heart, extrapolating the results from lung and esophageal studies to set 
guidelines for left-sided breast cancer radiotherapy is uncertain. Additionally, the 
majority of pre-clinical studies on this topic have used murine models; however, 
significant differences have been identified in comparison to human physiology. Further, 
large animal models have been suggested for easier  translation of basic science findings 
to clinical practice, as they offer a more representative scale model of cardiac human 
physiology than murine models(150). Here we examine the utility of 18F-FDG and 13N-
ammonia cardiac PET for the assessment of radiation induced myocardial inflammation 
and altered perfusion in a canine model.18F- FDG and 13N-ammonia PET have been 
previously validated as non-invasive means of quantifying cardiac inflammation(111) 
and myocardial perfusion(151), respectively.18F- FDG and 13N-ammonia PET can 
potentially quantify regional heterogeneity in inflammation and perfusion concurrently  
in association with the known patterns of regional dose deposition within the heart. In the 
current study, changes in the uptake of 8F-FDG and 13N-ammonia were quantified at 
baseline, 1 week post, and 4 weeks post external beam cardiac irradiation. Irradiation was 
designed to mimic the typical exposure observed during left-sided breast cancer 
radiotherapy. This study aims to probe the spatial and quantitative relationship between 
radiation dose-deposition and acute changes in perfusion and associated inflammatory 
response. 
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3.1 Materials and methods 
3.1.1 Study design 
Cardiac perfusion and inflammation imaging on five adult female, bred-for-research 
hounds (21 -26 Kg) was performed on a hybrid PET/MRI system (Biograph mMR; 
Siemens AG) at baseline, 1, and 4 weeks post cardiac irradiation (see Figure 3-1 for 
details). Animals were anesthetized during imaging/irradiation using propofol (4-6 
mg/kg) and maintained with 2% isoflurane. The study was approved by the Animal Care 
Committee of the Western University (Protocol 2014-005, Appendix D). The choice for 5 
subjects was supported by an a priori power analysis (G*power, Version 3.1.9.2). The 
required number of samples was calculated such that the study would have a statistical 
power ≥ 0.95, at a significance criterion (α-value) = 0.05. An estimated effect size was 
derived from literature comparing perfusion estimates in normal volunteers to 5 groups of 
patients with varying levels of myocardial ischemia(152). 
 
Figure 3-1: An overview of the longitudinal study is shown in panel A. Timing of the 
baseline, 1 week and 4 week follow-up PET/MRI imaging protocol is shown in panel 
B. Abbrev. CT-SIM – computed tomography radiotherapy simulation scan; IV – 
intravenous; MRAC – magnetic resonance attenuation correction. 
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3.1.2 Radiation treatment planning & delivery 
The radiation dose distribution was designed to resemble the typical cardiac exposure 
delivered during left-sided breast cancer radiotherapy. Dose volume histogram (DVH) 
metrics were obtained from 30 consecutive clinically treated left-sided breast cases at the 
London Regional Cancer Program (London, ON Canada). The 95% confidence intervals 
of the extracted DVH metrics were used as dose constraints for the heart and it’s 
substructures in this study. A detailed summary of the included patient treatment 
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characteristics and the derived dose constraints are provided in 
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Appendix B: Worked general solution to equation 1-1 
 
 𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)
𝑑𝑡
= 𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) −  𝐾2𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) 1-1 
begin by taking the Laplace transform of both sides of equation 1-1 
 𝐿 {
𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)
𝑑𝑡
} = 𝐿{𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) − 𝐾2𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)} 
 
in the Laplace domain we have the following equation 
 𝑠𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) − 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(0) = 𝜌𝐾1𝐶?̅?𝑙𝑜𝑜𝑑(𝑡) −  𝐾2𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) A-1 
where 𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) 𝑎𝑛𝑑 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(0) are the Laplace transform of 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 and the initial 
condition in the time domain respectively. Since the initial condition is equal to zero we 
can rearrange equation A-1 to solve for  𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) 
 𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) =
𝜌𝐾1?̅?𝑏𝑙𝑜𝑜𝑑(𝑡)
𝑠+ 𝑘2
  
 
𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) = 𝜌𝐾1𝐶?̅?𝑙𝑜𝑜𝑑(𝑡)
1
𝑠 + 𝑘2
 
 
The following equation is obtained by taking the inverse Laplace transform of both 
sides. Also, recall that multiplication in the Laplace domain is convolution in the time 
domain. 
 𝐿−1𝐶𝑡𝑖𝑠𝑠𝑢𝑒𝑡=𝐿−1𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑𝑡⊗𝐿−11𝑠+ 𝑘2  
 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) = 𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) ⊗  𝑒﷩ −  𝐾2𝑡  
  
61 
 
 
 
Appendix C and Appendix E respectively. All animals received a standard fast helical CT 
and a contrast enhanced CT (Discovery VCT; GE Healthcare) for radiation treatment 
planning. All subjects were ventilated using shallow breaths in order to minimize the 
need to correct for intrafraction respiratory motion.  Contours of the heart, left ventricle 
(LV), left circumflex(LCX), and LAD were manually delineated on the contrast 
enhanced CT for improved visualization. Myocardial regions of the left ventricle were 
further segmented in accordance with the 17 segment model as described by the 
American Heart Association( AHA)(153).  Complete contours were overlaid onto the 
non-contrast enhanced CT images for radiation treatment planning. Volumetric 
modulated arc therapy(154) (VMAT) radiation treatment plans were created using the 
Pinnacle3 treatment planning system (Phillips Radiation Oncology Systems). The 
treatment plans consisted of two, 180o, 6 MV photon arcs and deliberately focused on to 
the myocardial regions supplied by the LAD while intentionally avoiding the basal 
anterolateral portion of the LV and the LCX in order to compare cardiac function in 
irradiated vs minimally-irradiated segments. Dose was calculated using the adaptive 
convolve dose algorithm(155–157) implemented in Pinnacle3. 
During baseline imaging, tattoos, radio-opaque markers, and wall-mounted lasers were 
used to aid with re-positioning of the animals on the day of irradiation. Prior to treatment, 
cone-beam CT and intra-treatment fluoroscopic imaging were used to verify the position 
of the animal’s hearts during irradiation. 
The biological equivalent dose(158) of the multi-fractionated radiation prescriptions was 
delivered in a single fraction. An  α/β ratio of 2.5 Gy (159) was used to convert the multi-
fractionated scheme (~30 Gy in 25 fractions prescribed to a point within the LAD) to a 
single fraction delivery (~9 Gy in 1 fraction) (159). All animals were irradiated with a 
TrueBeam linear accelerator (Varian Medical Systems). 
3.1.3 Imaging 
Cardiac perfusion and inflammation was assessed using 13N-ammonia and 18F-FDG PET 
imaging, respectively (details outlined in Figure 3-1). 
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Cardiac perfusion was imaged both under pharmacological stress and at rest. 
Pharmacological stress perfusion was induced in all animals using 3 mg/min intravenous 
injection of adenosine over 10 minutes. Adenosine was injected prior to the manual bolus 
injection of 13N-ammonia (~5 MBq/Kg) followed by a saline flush. Rest perfusion was 
assessed with a second injection of 13N-ammonia. The data was acquired in list-mode and 
retrospectively binned into time periods using the bellows respiratory trigger.  The list 
mode data was grouped into 16 frames: 12x10s, 2x30s, 1x60s, 1x360s. All PET data was 
reconstructed using an iterative 3D ordered subset expectation maximization 
algorithm(OSEM)(160) with 3 iterations, 21 subsets,172x172x127 matrix size, and a 4-
mm Gaussian smoothing filter, yielding a voxel size of 2.08x 2.08 x 2.03 mm. The hybrid 
PET/MRI system corrects for random coincident events using the standard delayed 
window correction method. For scatter correction, a single scatter iterative algorithm is 
used. The scatter correction technique was originally described by Watson et al(161). The 
dead time is measured empirically and applied as a correction to the PET signal after 
normalization. 
Prato et al, (111) previously described and validated an 18F-FDG PET imaging protocol 
capable of identifying abnormal accumulation of inflammatory cells within the heart 
following coronary occlusion. The same imaging protocol is adopted here to study RICD. 
In order to image cardiac inflammation, the normal myocardial uptake of glucose was 
suppressed prior to the injection of 18F-FDG.  The suppression of glycolysis was achieved 
through fasting and an intravenous injection of heparin (2000 IU) immediately followed 
by a 20% lipid (Intralipid; Baxter Health-care Corp.) infusion (0.25 ml/min/kg; 50 min 
duration) 20 min prior to the injection of 18F-FDG. This myocardial suppression protocol 
was validated before the current study in 3 healthy subjects. The data was acquired in list-
mode 60 mins after the injection of 18F-FDG. A single static frame (20min duration; 
respiratory triggered) was reconstructed using OSEM. Attenuation was corrected for all 
PET scans using a 2-point Dixon MR imaging pulse sequence(124, 162), which 
automatically segments and substitutes discrete attenuation coefficients of lung, adipose 
tissue, and soft tissue. MR-based attenuation correction for cardiac PET has been 
previously validated and shown to be strongly correlated with standard CT-based 
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attenuation correction with narrow Bland-Altman limits of agreement (-8.5% to 
+12.6%)(23).  
3.1.4 Data Analysis 
Perfusion and inflammation results were grouped according to the typical canine 
coronary artery distribution(163).  Each of the 17 myocardial regions was classified as 
being predominately supplied by the LAD, LCX, or both arteries.   
Cardiac perfusion was quantified using a one-compartment tracer kinetic model(151) 
implemented using the semi-automated analysis program, FlowQuant© (University of 
Ottawa Heart Institute)(164). A unidirectional uptake rate constant, K1, from the arterial 
blood to the tissue compartment provides a direct estimate of myocardial perfusion 
(ml/min/g). This assumption has been previously shown to be valid since the tracer 
extraction for 13N-ammonnia is >92%(151, 165) for flows up to 6 ml/min/g. In general, 
K1 is obtained from the deconvolution of the imaged-derived tissue tracer concentration 
curve (obtained from each of the 17 myocardial segments) and the arterial input function 
(obtained from a region interest within the left ventricular blood pool). The 1-
compartment model derivation of the relationship between the measured tracer 
concentration in the blood, tissue, and the estimated K1 and K2 values is provided in 
Appendix B.  The K1 and K2 value is estimated through an iterative approach minimizing 
the cost function defined in equation 3-1. 
 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) − 𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) ⊗ 𝑒
−𝐾2𝑡 3-1 
Changes in cardiac inflammation were analyzed as changes in the mean standard uptake 
value (SUVmean) and standard uptake ratio (SUR). The definition of the SUV is provided 
in equation 3-2. 
 
𝑆𝑈𝑉 =
Activity in myocardial region (MBq)/regional volume (ml)
Injected activity (Mbq)/ subject weight (g) 
 
3-2 
The SUR has been previously reported as a means of reducing inter-study variation. The 
SUR value is obtained by normalizing the SUVmean by the SUV within the aorta(166). 
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SUVmean and SUR were computed for all 17 myocardial regions defined by the AHA. For 
statistical comparison, the 17 myocardial regions were aggregated and grouped based on 
coronary regions (LAD vs LCX vs Both), axial regions ( basal vs mid-ventricle vs apex), 
and radial regions ( lateral wall vs inferior wall vs anterior wall vs septal wall). Table 3-1 
proves further details regarding this regional grouping. 
Table 3-1: Grouping of American Heart Association 17 segment model for statistical 
comparisons 
Comparison Group 1 Comparison Group 2 Comparison Group 3 
coronary regions AHA segment Axial Regions AHA segment Radial Regions AHA segment 
LAD 1, 2, 7, 8, 13 Basal 1-6 Anterior wall 1, 7, 13 
LCX 4, 5, 10, 11, 15 Mid-ventricular 7-12 Septal wall 2, 3, 8, 9, 14 
Both 3, 6, 9, 12, 14, 
16, 17 
Apex 13-17 Lateral wall 5, 6, 11, 12, 16 
    Inferior wall 4, 10, 15 
All statistical analyses were performed using SPSS 23 (IBM Corp.). Differences in 
cardiac perfusion and inflammation before and after irradiation and regional differences 
between myocardial regions supplied by the LAD and LCX were tested using a 
multivariate two-way repeated measures analysis of variance. Bonferroni post hoc 
analysis was used to correct for multiple comparisons. Pearson’s product-moment 
correlation coefficient was used to test the association between regional dose deposition 
and changes in perfusion/inflammation. All data are reported as mean ± standard error of 
the mean (SEM) unless otherwise indicated. 
3.2 Results 
The average regional dose, injected dose of all radiotracer, and plasma glucose levels 
(PGL) prior to imaging are tabulated in  
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Appendix F. No statistically significant differences were observed between scans for the 
injected doses of 13N-ammonia and 18F-FDG. Although no statistically significant 
differences were found between PGL, the baseline PGL and PGL at 4 weeks did 
approach statistical significance (p =0.055). Mean doses delivered to the heart (1.7 Gy), 
LV (2.7 Gy), LAD (5.5 Gy), and LCX (1.1 Gy) are typical of values observed in left-
sided breast cancer radiotherapy patients. Figure 3-2 shows the computed radiation dose 
distribution superimposed onto the contrast-enhanced CT image for a representative 
subject. Figure 3-3 shows the DVH’s for the heart, LAD, and LV of a representative 
subject in comparison with DVH’s of two patients analyzed in Chapter 2. 
 
Figure 3-2: A coronal, contrast-enhanced CT slice (panel A) showing the heart, left 
ventricle (LV), left anterior descending artery (LAD), and left circumflex artery 
(LCX) contours on a representative subject (subject 3). The spatial distribution of 
the radiation dose is shown in panel B. The basal anterolateral portion of the LV 
and the LCX were intentionally avoided (see panel B) in order to compare cardiac 
function in irradiated vs non-irradiated segments. 
A statistically significant increase in the 18F-FDG SUVmean and SUR was observed post 
irradiation. Increased cardiac uptake of 18F-FDG was found throughout the entire LV, 
including targeted and un-targeted myocardial regions (see Figure 3-4). The change in 
SUVmean and SUR aggregated from all 5 subjects is presented in Figure 3-5. A correlation 
could not be established between regional dose and differences in uptake of 18F-FDG 
relative to baseline.  
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A statistically significant increase in both rest and stress 13NH3 perfusion was observed 
post cardiac irradiation. Static 13NH3 cardiac PET uptake images are shown for a 
representative subject (subject 3) in Figure 3-6. Increased stress perfusion was found 
throughout the entire LV, with no statistically significant difference between regions 
regardless of regional dose magnitude (see Figure 5). Linear regression analysis between 
dose and perfusion did not reveal any significant relationships between dose and 
perfusion effects. The FDG uptake and resting state perfusion appear to progressively 
increase within the first 4 weeks following cardiac irradiation. 
3.3 Discussion 
The risk of RICD after left-sided breast radiotherapy is substantiated by several 
epidemiological studies; however, the early events and progression of the disease still 
remain unclear. RICD is considered a significant health problem due to the large number 
of women receiving radiotherapy for breast cancer(17, 32, 127) and surviving to an older 
age where cardiac issues become evident. This study demonstrated that focal cardiac 
irradiation to the LAD with heart doses comparable to that of standard breast irradiation 
techniques results in an early increase in 18F-FDG uptake and myocardial perfusion. This 
study also demonstrates that these changes can be detected as early as 1 week post 
irradiation.  It should be noted that collateral cardiac irradiation as a consequence of 
breast radiotherapy is typically delivered with 30 dose fractions. However, this study was 
performed using a single irradiation.  In this study, the delivered single fraction dose was 
set using a previously reported 𝝰/𝝱 ratio  of 2.5 Gy(159).  Evidence exists regarding the 
validity of applying the linear quadratic model for single fraction deliveries(167), 
although this matter is still debated (168, 169).  
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Figure 3-3: Cumulative dose volume histogram comparison between human and 
canine cohorts for the heart, LAD, and LV. 
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Figure 3-4: 18F-FDG SUV PET images of a representative subject (subject 3) at 
baseline, 1 week and 4 weeks post cardiac irradiation. 
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Figure 3-5: Changes in 18F-FDG mean standard uptake value (SUVmean) and 
standard uptake ratios (SUR) obtained from regions of interest within the left 
ventricle pre and post cardiac irradiation. Panels along the left and right column 
represent changes in SUVmean and SUR respectively. Uptake in panels A and B are 
grouped by myocardial regions supplied by the left anterior descending (LAD) 
and/or the left circumflex artery (LCX). Uptake in panels C and D are grouped by 
basal, middle (Mid) and apical (apex) myocardial regions. Uptake in panels E and F 
are grouped by inferior, lateral, anterior, and septal myocardial regions. The mean 
dose delivered is reported in the legend, error bars indicate the standard error of 
the mean, and statistically significant differences are indicated by horizontal lines 
spanning the comparison points as *p<0.05 and **p<0.01. 
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Figure 3-6: 13NH3 standard uptake value (SUV) PET images of a representative 
subject (subject 3) at baseline, 1 week and 4 weeks post cardiac irradiation. Images 
are reconstructed from list-mode data acquired 4 - 10 minutes post radiotracer 
injection.   
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Figure 3-7: Changes in 13N-ammonia myocardial perfusion obtained from regions of 
interest within the left ventricle pre and post cardiac irradiation. Panels along the 
left (i) and right (ii) columns represent perfusion changes observed at rest and 
under pharmacological stress respectively. Panels A. i) and ii) are grouped by 
myocardial regions supplied by the left anterior descending (LAD) and/or the left 
circumflex (LCX). Panels B. i) and ii) are grouped by basal, middle (Mid) and apical 
(apex) myocardial regions. Panels C. i) and ii) are grouped by inferior, lateral, 
anterior, and septal myocardial regions. The estimated dose delivered is reported in 
the legend, error bars indicate the standard error of the mean, and statistically 
significant differences are indicated by horizontal lines spanning the comparison 
points as *p<0.05 and **p<0.01. 
It is believed that the earliest morphological changes to heart after irradiation are related 
to the microvasculature. Pre-clinical evidence supports the hypothesis that an 
inflammatory response following cardiac irradiation is a precursor and the mechanism for 
the evolution of RICD(19). Here we have shown that during the suppression of 
competing myocardial glucose uptake, a global increase in 18F-FDG uptake is triggered in 
response to focused cardiac irradiation. We hypothesize that this increased uptake is 
indicative of systemic inflammatory response to the radiation. The merits of this imaging 
approach has been previously shown for assessing inflammation in cardiac 
sarcoidosis(110) and after myocardial infarction(111). However, the ability to 
successfully suppress the normal 18F-FDG physiological uptake by myocardium is 
difficult to verify and a potential limitation of this technique. Additionally, it has been 
previously reported that anesthesia through the use of isoflurane may reduce the 
suppressive effects of fasting and heparin on myocardial glucose utilization in mice(170).  
Although we cannot be completely certain that  full glucose suppression was achieved in 
this study, we have shown depressed SUV values (Figure 3) at baseline and follow up in 
comparison to previously reported SUV values without suppression(171). Furthermore, 
although the imaging protocol was consistent throughout the study, we cannot completely 
rule out potential for variability in the level of suppression between subjects and/or time 
points and the spatial heterogeneity of suppression within subjects. Thus, additional tests 
such as histopathology would be required to confirm the presence of inflammation. 
74 
 
 
 
Unfortunately, histopathology confirmation could not be included since subjects were not 
sacrificed at the conclusion of this acute study. 
We observed similar heterogeneity in 18F-FDG uptake throughout the different planes of 
the LV compared to findings in previously reported literature(172, 173). Increased uptake 
was observed in the mid and apical planes compared to the basal plane. No statistically 
significant variation was found between inferior, lateral, anterior, and septal LV regions. 
However, the trend in Figure 3-5, panel E is in agreement with the expected spatial 
variation in uptake(174). 18F-FDG uptake tends to be higher in the lateral and inferior 
walls than the anterior wall and septum of normal myocardium. Three early explanations, 
one technical and two physiological were previously provided for the observed 
heterogeneity in normal myocardial FDG uptake, however they were refuted. In axial 
PET images the septal/anterior LV walls appear thinner than the inferior/lateral walls. 
Consequently, it was reasonably hypothesized that counts would be reduced in the 
thinner portions of the LV.  Additionally, potential variability in regional perfusion and 
contractile work load of the LV has been previously provided as explanations for the 
heterogeneous uptake. However, all three explanations were later refuted through the use 
of 11C-acetate (myocardial oxygen consumption tracer) and 15O-water (perfusion tracer) 
PET imaging(175). Groppler, et al, showed homogeneous myocardial perfusion and 
clearance of 11C-acetate from normal myocardium, suggesting that the previous 
explanations for the heterogeneous uptake of FDG are unlikely. To the best of our 
knowledge, no further explanations have been provided in the literature. All that we 
know is that this heterogeneity is commonly observed(172, 174).      
No correlation was found between the dose delivered to specific myocardial regions and 
the change in uptake relative to baseline, i.e. the areas of higher radiation dose did not 
appear to have greater increases in perfusion or FDG uptake with greater dose. To the 
best of our knowledge, this dose-independent uniform global inflammatory response at 1 
week post irradiation in the heart at dose levels comparable to what is observed in the 
breast cancer population is a novel finding. The lack of correlation with dose magnitude 
may be due to the small number of animals used in this study and also by the relatively 
few myocardial regions with exposures below 1 Gy. Approximately 8% and 1% of the 
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total number of contoured LV regions received doses less than 1 Gy and 0.5 Gy, 
respectively. The clinical implication of this finding supports the recent interest in the use 
of standard heart failure therapies such as ACE inhibitors as a potential strategy to reduce 
the risk of RICD(176). 
Clinical assessments  of myocardial perfusion post left-sided breast radiotherapy 
consistently report reductions in myocardial perfusion at least 6 months after 
radiotherapy (43, 45, 47, 59, 99, 177–180).  However, results from this study show an 
increase in myocardial perfusion 1 week after cardiac irradiation by approximately 20% 
relative to baseline. This finding suggests that a transient increase in perfusion (~1 week 
post irradiation) due to a global inflammatory response may precede reductions in 
perfusion observed at 6 months. This may develop as a result of late fibrotic changes 
within either myocardium or epicardial vessels leading to hemodynamically significant 
stenoses. This increase in perfusion is in line with two pre-clinical studies in murine 
models(181, 182). Lauk et al(181) and Seeman et al(182) observed increases in 
endothelial cell proliferation (3 weeks post irradiation) and increases in microvascular 
density 20 weeks following cardiac irradiation respectively. Additionally, an increase in 
vascular permeability has been reported in mice, 4 weeks after partial cardiac 
irradiation(80). 
The uncertainty in the quantification of myocardial perfusion using 13NH3 PET has been 
previously reported as approximately 10%(104, 105). It is believed to be dominated by 
variation in cardiac motion, signal noise, errors in compartmental modeling, partial 
volume effects, spillover from the right ventricular blood pool/adjacent liver activity, and 
potential errors in image registration between time points.  However, the mean increases 
in perfusion after cardiac irradiation relative to baseline shown here are greater than the 
expected overall reported uncertainty in perfusion estimation.  
It should be noted that the absolute measures of stress perfusion reported here appear to 
be reduced in comparison to literature values with similar adenosine administration 
protocols. This was a consistent finding in all animals and it is speculated that it may be 
related to the dose of adenosine. This prompted an additional stress 13NH3 PET scan in 
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two animals with a double dose of adenosine; however, perfusion results at the double 
dose still remained blunted. Previous studies have also reported difficulties with the use 
of intravenous adenosine infusion in comparison to dipyridamole in the quantification of 
myocardial blood flow in canines(151). 
A potential limitation of this study is the canine animal model differs in comparison to 
human hearts with regards to the increased number of collateral vessels. However, the 
impact of this difference on the translation of these findings to humans is not currently 
known. Further work using other large animal models such as pigs with reduced 
collateral circulation may be needed.  
It should be noted that although the study was performed using a hybrid PET/MRI 
scanner, all of the techniques presented can also be implemented using PET/CT.   
3.4 Conclusion 
These early findings post cardiac irradiation echo the previous pre-clinical literature 
using mice. However, the results from this study are presented in a large animal model 
which more closely resembles the vessel architecture of humans than murine models.  
Additionally, the findings are reported using a clinical imaging system and protocol that 
can be easily modified for use in human studies. In light of these findings, we suggest the 
use of this imaging approach for future human studies attempting to assess the clinical 
efficacy of approaches to minimize cardiac exposure during left-sided breast irradiation. 
Specifically, the efficacy of techniques aimed at reducing the risk of RIHD such as the 
administration of anti-inflammatory medications (ex. ACE-inhibitors) may potentially be 
assessed at much earlier time points through the use of 18F-FDG inflammation and/or 
13NH3 perfusion PET imaging. 
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Chapter 4  
4 The utility of 18F-FDG and 13N-ammonia PET for 
monitoring the progression of cardiac inflammation and 
perfusion following focused cardiac irradiation in 
canines 
Chapter 4 hypothesis: A reduction in left ventricular perfusion and an enhancement in 
inflammation is related to local radiation dose levels within the heart. 
Cancer patients receiving radiotherapy for the treatment of thoracic malignancies such as 
lung, breast, and esophageal are at risk of radiation-induced cardiovascular disease 
(RICD). RICD is believed to be dose-dependent and can lead to the following:  
pericarditis, valvular dysfunction, fibrosis, and/or coronary artery disease (32). Acute 
pericarditis and valvular dysfunction are less prevalent today due to technological 
advances in radiotherapy that have led to significant reductions in incidental cardiac 
exposure. However, the more latent manifestation of RICD, coronary artery disease, is 
still prevalent in both the “high-dose”(183) and “low-dose”(17) patient populations. A 
recent clinical trial (183) (RTOG 0617) comparing radiation dose regimens for the 
treatment of lung cancer, suggests that the benefit of high-dose deposition to lung 
tumours may be outweighed by the risks associated with increased cardiac irradiation. 
Furthermore, there is substantial interest in new treatment strategies aimed at reducing 
cardiac toxicity following left-sided breast irradiation (17, 21, 43, 149, 184). Despite the 
recognition of RICD as a significant hurdle in improving patient survival, our 
understanding of the evolution of RICD is limited to preclinical studies in murine models 
(49, 51, 185). In order to study RICD progression in humans, non-invasive means for 
assessing cardiac toxicity with sufficient sensitivity to detect subtle changes before they 
become clinically significant is needed.  
Positron emission tomography (PET) imaging coupled with 13N-ammonia (13NH3) and 
18F-fluorodeoxyglucose (FDG) are promising radiotracers for non-invasive, longitudinal 
assessment of cardiac perfusion and inflammation respectively. The use of 13NH3 PET 
has been previously validated and widely considered the gold-standard in the assessment 
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of cardiac perfusion non-invasively in humans (151, 186). The motivation to assess 
myocardial perfusion comes from preclinical studies suggesting that radiation injury to 
the microvasculature precedes RICD (52). Myocardial perfusion has been previously 
studied in the context of RICD through the use of single photon emission computed 
tomography (45, 47, 59, 99, 180, 187). SPECT studies suggest that perfusion changes are 
expected in patients where at least 5% of the left ventricle is within the field (defined by 
the 50% isodose line). However, to the best of our knowledge a direct correlation 
between dose magnitude and changes in perfusion has not been previously reported. The 
use of PET imaging has an advantage over SPECT due to the ability to provide absolute 
quantification of myocardial perfusion using dynamic data acquisitions and tracer kinetic 
modelling (188). Quantitative approaches to perfusion assessment have shown to be more 
sensitive and more specific (189) in identifying myocardial perfusion abnormalities, 
which is the typical pattern within the first decade after incidental cardiac irradiation 
during radiotherapy. Additionally, due to the short half-life (~10mins), 13NH3 may be 
coupled with FDG PET in a single imaging session. FDG PET has been previously used 
to assess cardiac inflammation in cardiac sarcoidosis (110) and following myocardial 
infarction (111). Similar to perfusion abnormalities, preclinical studies have shown 
evidence of an inflammatory response following cardiac irradiation and preceding RICD 
(19). Although FDG cardiac PET imaging studies in the context of RICD exist, they are 
limited to studies where radiation dose to the heart are more relevant to lung and 
esophageal patients (41, 114–116, 190, 191). Extrapolating the lung and esophageal 
radiotherapy findings to the breast cancer population is questionable considering the 
significant differences in mean dose to the heart. Previous to Chapter 3 of this thesis and 
to the best of our knowledge, FDG PET has not been used to assess cardiac inflammation 
after exposure levels that are typically observed following left-sided breast radiotherapy.  
The purpose of this study was to examine the utility of 13NH3 and FDG PET in 
monitoring the evolution of cardiac perfusion and inflammation following cardiac 
external beam irradiation. Cardiac inflammation and perfusion imaging was repeated 
over 12 months in a canine model before and following cardiac irradiation. Unlike 
previous studies, cardiac irradiation was designed to mimic the typical heart exposure 
observed after left-sided breast radiotherapy. In addition to non-invasive PET imaging, a 
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preliminary histological analysis of the excised heart from a representative subject was 
conducted 12 months following cardiac irradiation. 
4.1 Materials and methods 
4.1.1 Study design 
The study design is outlined in Figure 4-1. Five bred-for –research female hounds (21-26 
kg) underwent cardiac perfusion and inflammation PET imaging at baseline, and 3 
months, 6 months, 12 months following focused cardiac external beam irradiation. At 12 
months, the animals were sacrificed and the hearts were excised for histological staining. 
The study was approved by the Animal Care Committee of the Western University 
(Protocol 2014-005).  
 
Figure 4-1: The study design and imaging time-points are outlined in panel A. The 
PET/MRI imaging protocol performed each session is shown in panel B. In addition 
to the PET/MRI imaging, the baseline imaging session included contrast and non-
contrast enhanced computed tomography (CT) imaging for organ delineation and 
radiation treatment planning, respectively. Abbrev. IV – intravenous; MRAC – 
magnetic resonance attenuation correction. 
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4.1.2 Imaging 
The cardiac perfusion and inflammation PET imaging protocol (details in Figure 4-1, 
panel B) was conducted on a hybrid PET-MR scanner (Biograph mMR; Siemens AG).  
All radiation and imaging sessions were conducted using general anesthesia with 
propofol for induction and 2% isoflurane to maintain a surgical level of anesthesia.   A 2-
point Dixon pulse sequence was used for MRI-based attenuation correction. The 2-point 
Dixon provides bulk substitution of attenuation coefficients for regions identified as fat 
and water (124, 162). Good agreement between the 2-point Dixon method and CT-based 
attenuation correction has been previously shown for cardiac PET imaging (162).   
Cardiac perfusion was imaged using 13NH3 with list-mode PET acquisition reconstructed 
into 16 dynamic frames (12x10s, 2x30s, 1x60s, 1x360s). PET data was reconstructed 
using an ordered-subset expectation maximization algorithm (OSEM)(160) with 21 
subsets, 3 iterations, 4-mm Gaussian smoothing filter, and 172x172x127 matrix size, 
yielding a voxel size of 2.08x2.08x2.03 mm. Each animal was manually injected with a 
bolus of ~5 MBq/Kg of 13NH3 radiotracer followed by a saline flush. In order to estimate  
the myocardial perfusion reserve (MPR), each animal received two separate 13NH3 
injections, one at resting-state and another during  pharmacological stress (following a 3 
mg/min intravenous injection of adenosine over 10 minutes).  Cardiac perfusion was 
quantified in units of ml/min/g using a 1-compartment tracer kinetic model (107) 
implemented using a semi-automatic software package, FlowQuant© (University of 
Ottawa Heart Institute). Perfusion was quantified for each of 17 left ventricular segments 
using  the American Heart Association(AHA) model (153).  
Cardiac inflammation was imaged using FDG PET after the suppression of the normal 
physiological uptake of glucose by the myocardium. As described previously (111), 
normal myocardial glucose uptake was suppressed through fasting and an intravenous 
injection of unfractionated heparin (2000 IU) followed by a 20% lipid (Intralipid; Baxter 
Health-care Corp.) infusion beginning 20 min prior to the injection of FDG. The mean 
standard uptake value (SUV) was calculated from a respiratory gated, static PET 
acquisition acquired 60 min after the injection of FDG. Similar to the perfusion analysis, 
the SUV was quantified using the AHA 17 segment model. 
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4.1.3 Radiation delivery 
Each animal received a contrast enhanced and non-contrast enhanced fast helical 
computed tomography scan (Discovery VCT; GE Healthcare) for organ delineation and 
radiation delivery planning, respectively. Contours of the heart, left ventricle (LV), left 
anterior descending artery (LAD), and left circumflex artery (LCX) were initially 
generated on the contrast enhanced CT and then migrated to the registered non-contrast 
enhanced CT. The non-contrast enhanced images and contours were transferred to a 
clinical treatment planning system (Pinnacle3; Phillips Radiation Oncology Systems) for 
radiation treatment planning. The treatment plan was designed to mimic the typical 
cardiac exposure observed during left-sided breast radiotherapy. Dose-volume histogram 
(DVH) metrics for the heart, LV, and LAD were obtained from 30 consecutive patients 
previously treated for left-sided breast cancer.  The 95% confidence intervals of the DVH 
metrics were implemented as constraints in the development of the radiation plan for this 
study. All animals received volumetric modulated arc therapy(154) (VMAT) plans 
consisting of two, 180o, 6MV photon arcs that were deliberately focused onto myocardial 
regions supplied by the LAD. In addition, dose to the LCX and the basal anterolateral 
portion of the LV was minimized in order to compare cardiac function in irradiated and 
less-irradiated myocardial segments. The dose distribution was calculated using the 
adaptive convolve dose calculation algorithm (155, 157, 192).   
 In patients, radiation is typically delivered in multiple fractions. However, in this study a 
biological equivalent dose (158) of the multi-fractionated treatment was delivered in a 
single fraction. The multi-fractionated prescription (~30 Gy in 25 fraction prescribed to a 
point within the LAD) was converted to a single fraction prescription using an α/β of 2.5 
Gy (~9 Gy in 1 fraction) (159). All animals were irradiated using a TrueBeam linear 
accelerator v1.6 (Varian Medical Systems, Palo Alto, USA). Radio-opaque markers, 
wall-mounted lasers, and tattoos were used to aid in re-positioning the animal on the 
accelerator. Image guidance through pre-treatment cone-beam CT and during treatment 
fluoroscopy were used for additional setup verification.  
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4.1.4 Histological analysis 
A representative subject was selected for histological analysis. All animals were 
euthanized using using an intravenous injection of potassium chloride. The isolated hearts 
were rinsed with phosphate-buffered saline and fixed through aortic infusion of 10% 
formalin and then fixed with formalin at room temperature for at least one week. The 
fixed heart was embedded in 3.5% agar (Sigma A7002) and then sliced into 4.4 mm-thick 
cross sections. The heart tissues were sampled according to standardized 17 segment 
myocardial segmentation guideline for tomographic imaging as specified by the 
American Heart Association (153). The segmented heart tissues were processed and 
embedded in paraffin. Five-micron paraffin sections from each segment were stained 
with hematoxylin and eosin for histology. Myocardial inflammation was assessed via 
immunohistochemistry for CD45, a common leukocyte antigen, on tissue sections. CD45 
was immunostained using a rabbit polyclonal CD45 antibody (ab10558, Abcam). Bound 
antibodies were visualized using ABC reagent and diaminobenzidine (Vector 
Laboratories). The bright-field images were acquired under Olympus BX-51 light 
microscope. The abundance of CD45-immunoreactive cells was visually quantified in a 
random high powered (40X) field at the anterior-septal region within the apex of the left 
ventricle. 
4.1.5 Data analysis 
Mean values of myocardial perfusion, perfusion reserve, and inflammation were 
compared to baseline values using a multivariate two-way repeated measures analysis of 
variance (ANOVA). A bonferroni post hoc test was used to correct for multiple 
comparisons. Perfusion and SUV values were grouped by anatomical region and also in 
accordance with the typical canine coronary artery distribution (163). Each myocardial 
segment was classified as being supplied by the LAD and/or the LCX artery. The 
relationship between dose deposition and changes in cardiac perfusion/inflammation was 
also assessed through Pearson’s product-moment correlation coefficient (R2). All 
statistical tests were performed using SPSS 23 (IBM Corp.) and all values are reported as 
mean ± standard error of the mean (SEM) unless otherwise indicated. 
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4.2 Results 
The blood plasma glucose levels, injected 13NH3 activity, and injected FDG activity 
during all imaging sessions is tabulated in Appendix F. All animals received cardiac 
external beam irradiation that was deliberately focused onto the LAD. The spatial dose 
distribution can be visualized for a representative subject in Figure 4-2. The mean 
radiation dose delivered for the 5 animals to the heart, LV, LAD, and LCX was 1.7±0.1 
Gy, 2.7±0.1 Gy, 5.5±0.3 Gy and 1.1± 0.2Gy, respectively. Delivered doses to the heart 
and substructures for each individual subject are tabulated in Appendix F.   
Cardiac inflammation was assessed through the comparison of cardiac FDG uptake at 
baseline and following cardiac irradiation. The uptake of FDG in the LV myocardium 
was increased in comparison to baseline for all animals. Figure 4-3, panel A shows the 
increased FDG PET uptake in the heart, 12 months after cardiac irradiation for a 
representative subject. The histological images following irradiation from the same 
subject represented in the PET images is shown in Figure 4-3, panel B. Figure 4-3, panel 
B show both the standard H and E staining as well as CD45 staining highlighting 
persistent inflammatory cell activity at 12 months. Hematoxylin and eosin staining did 
not identify any signs of fibrosis, or morphological damage to the LV wall. Irregular 
endothelial cell morphology along the inner lumen of some arterioles and arteries were 
also present.   
Figure 4-4 shows a linear increase in SUV over the first 6 months.  The increased uptake 
of FDG relative to baseline was found to be statistically significant at all time points 
following cardiac irradiation (p<0.01). The changes in FDG uptake compared to baseline 
uptake were global and did not vary in response to the administered radiation dose with 
no significant correlation found between regional dose and changes in FDG uptake 
relative to baseline.  
Changes in cardiac perfusion were monitored through 13NH3 dynamic PET imaging 
coupled with tracer kinetic modeling for absolute quantification of perfusion. An increase 
in adenosine stress perfusion was observed throughout the entire LV at 3 months and 6 
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months following cardiac irradiation (p<0.01). However, by 12 months the stress 
perfusion had declined to near baseline levels.  
 
Figure 4-2: Transverse, sagittal, and coronal contrast-enhanced CT slices (panel A) 
showing the heart, left ventricle (LV), LAD, and LCX contours of a representative 
subject. The radiation dose distribution is overlaid  onto the anatomy in panel B. 
Dose to the basal anterolateral portion of the LV and the LCX artery were 
intentionally minimized (see panel B) in order to compare cardiac function in 
irradiated vs less-irradiated segments. 
Figure 4-5 and Figure 4-6 show similar changes in perfusion relative to baseline in both 
areas of higher and lower radiation dose deposition. Similar to the FDG findings, no 
significant correlation was found between regional dose and changes in perfusion relative 
to baseline. A statistically significant increase in resting-state perfusion was observed at 6 
and 12 months (p<0.01).  Rest perfusion estimates in basal myocardial regions were 
higher than in the apex of the left ventricle.  Changes in myocardial perfusion reserve 
relative to baseline were only observed at 3 months post irradiation (p<0.01).  
Unfortunately, rest perfusion estimates at the 12 month time-point for subject 2 were not 
obtained due to a technical issue during data acquisition.   
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Figure 4-3: Panel A. Transverse and sagittal image slices of the 18F-FDG standard 
uptake before and 12 months after cardiac irradiation for a representative subject 
(subject 3). Panel B.  Histological slides from the left ventricular myocardium. 
Hematoxylin and eosin staining and CD45 antigen immunohistochemistry staining 
show cellular morphology and the presence of inflammatory cells respectively. 
CD45 positively stained inflammatory cells (leukocytes) within the myocardium are 
indicated by red arrows.   
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Figure 4-4: The temporal progression of 18F-FDG standard uptake within the left 
ventricle myocardium. Uptake in panel A is grouped by myocardial regions 
supplied by the left anterior descending (LAD) and/or the left circumflex (LCX). 
Uptake in panel B is grouped by inferior, lateral, anterior, and septal myocardial 
regions. Uptake in panel C is grouped by basal, middle (Mid) and apical (Apex) 
myocardial regions. The estimated dose delivered is reported in the legend, error 
bars indicate the standard error of the mean, and statistically significant difference 
were observed between all time points (p<0.01). 
 
Figure 4-5: The delivered radiation dose distribution (panel A) and adenosine stress 
myocardial perfusion values at baseline and 3 months, 6 months, and 12 months 
post cardiac irradiation (panel B). Dose and perfusion values are overlaid onto a 
model of the left ventricle myocardium for a representative subject (subject 3).   
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Figure 4-6: Changes in 13N-ammonia myocardial resting-state perfusion (i), 
adenosine induced stress perfusion (ii), and myocardial perfusion reserve (iii) pre 
and post cardiac irradiation. Panels A. i), ii), and iii) are grouped by basal, middle 
(Mid) and apical (apex) myocardial regions. Panels B. i), ii), and iii) are grouped by 
inferior, lateral, anterior, and septal myocardial regions. The estimated dose 
delivered is reported in the legend, error bars indicate the standard error of the 
mean, and statistically significant difference are indicated by horizontal lines 
spanning the comparison points as *p<0.05 and **p<0.01. 
4.3 Discussion 
The progressively increasing uptake of FDG in the myocardium is suspected to be due to 
the infiltration of inflammatory cells in response to cardiac irradiation. This finding is 
further supported though ex-vivo images of CD45 positively stained cells within the 
myocardium. A similar pattern of inflammatory response following cardiac irradiation 
has been previously shown in mice (48, 52, 182). Through the use of flow cytometry, 
Sievert et al was able to show increases in endothelial cell surface markers related to 
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inflammation and proliferation that remained elevated up to 20 weeks post 
irradiation(52). The inflammatory response to cardiac irradiation has been previously 
associated with structural damage to the myocardium and microcirculation (182); 
however, hematoxylin and eosin staining of ex-vivo samples here did not result in 
evidence of structural damage due to radiation. Since structural damage is usually 
preceded by the inflammatory response, we suspect that this may have been observed in 
our study had we extended the follow-up period beyond 12 months, even though 
perfusion, in an absolute sense, was never compromised.   Our results parallel the 
findings of preclinical studies in mice, although our study used a large animal model and 
a clinical system capable of non-invasive imaging of human subjects. The large animal 
model such as the canine provides a more representative model of the human cardiac 
anatomy then mice (150). Further, the canine inflammatory response to myocardial 
infarction has also been shown to be much closer to humans than the murine model, 
where an accelerated pattern of inflammation is seen, much faster than observed in 
patients.   Additionally, large animal models facilitate the translation of basic science 
findings into clinical practice, specifically in the development of diagnostic imaging 
protocols to be used in human studies.  These findings support recent interest in the use 
of ACE inhibitors for radioprotection of the heart (176) and the potential for FDG PET to 
assess its efficacy. Although the typical use of ACE inhibitors is related to reducing 
hypertension, studies have shown potential anti-inflammatory action capable of reducing 
the reactive oxygen species created during tissue irradiation (193). However, additional 
work is still needed to provide evidence of a link between cardiac inflammation and 
future radiation induced cardiac toxicity. This link must be made in order to fully support 
the use of FDG for assessing the efficacy of ACE inhibitors.  
The 13NH3 PET results show a transient increase in both rest and stress perfusion 
following cardiac irradiation. To the best of our knowledge, no previous studies have 
shown increases in quantitative myocardial perfusion following cardiac irradiation. 
Previous clinical cardiac perfusion studies of left-sided breast cancer patients following 
cardiac irradiation have mixed results and are limited to qualitative assessment of SPECT 
images only. Zellars et al showed both regional increases and decreases in myocardial 
perfusion scores 6 months after radiotherapy(43). Conversely, other studies have shown 
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reductions in cardiac perfusion following radiotherapy  in ~50% of left sided breast 
cancer patients (45, 97, 100, 187). Chung et al did not observe any clinically significant 
SPECT perfusion defects 6 months following left-sided breast radiotherapy(46). 
Lawrence et al reported that the incidence of new perfusion defects 6, 12, 18, and 24 
months after radiotherapy was 27%, 29%, 38%, and 42%, respectively(47). In our study, 
two of the 5 subjects had 12 month stress perfusion estimates below baseline estimates, 
consistent with the incidence rates reported by Lawrence et al(47). However, the regional 
changes in perfusion in these two animals were not found to be correlated with the 
regional dose. After aggregating the results from all subjects, we did not identify 
statistically significant perfusion defects compared to baseline. The transient increase in 
perfusion following irradiation shown here is supported by several murine studies that 
have reported increases in endothelial cell proliferation, increases in microvascular 
density, and increases in vascular permeability following cardiac irradiation, presumably 
as an additional paired response associated with both the acute  and sub-acute 
inflammatory response out to 6 months  (181, 182).   
Increased FDG uptake and myocardial perfusion were observed globally, affecting both 
irradiated and “less” irradiated regions of the heart. This finding supports the conclusion 
by Darby et al, suggesting that there may not be a dose threshold for which there is no 
added risk of ischemic heart disease(17). In this study, approximately 8% and less than 
1% of the LV wall received doses below 1 Gy and 0.5 Gy, respectively.  We speculate 
that focal changes in FDG uptake and or perfusion related to dose deposition would 
require a more highly conformal delivery of radiation and a greater number of subjects 
than presented here. However, this type of irradiation would be less-representative of the 
left-sided breast cancer population.    
The broad extrapolation of the findings presented from this study to the clinical 
population is limited by the small number of animals assessed as well as other factors 
outlined below. Stress perfusion and perfusion reserve values reported here are blunted in 
comparison to literature values. This finding was consistent for all animals and present in 
both pre and post cardiac irradiation scans. Suspicion that this may be due to the dosage 
of adenosine injected for vasodilation prompted an additional experiment in two animals 
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at 6 months with twice the dose of adenosine. The increased dose did not result in any 
significant increases in stress perfusion either in absolute values or perfusion reserve. 
Previous studies have also reported difficulties inducing a stress response using 
adenosine infusion in the quantification of myocardial perfusion in canines (151). Lastly, 
incidental cardiac irradiation following breast cancer radiotherapy is typically delivered 
in multiple fractions; however, here the biological equivalent dose to the heart was 
delivered in a single fraction. Literature support exists for the validity of applying the 
linear quadratic model for single fraction deliveries (167);  however this matter is still 
debated(168, 169). A recent study focusing on stereotactic ablative radiotherapy has 
suggested the use of a hybridization of the linear quadratic model and the multi-target 
model to improve estimates of the biological equivalent dose for single fraction 
deliveries(194). The estimated biological equivalent dose is also sensitive to uncertainty 
in the accuracy of the alpha/beta reported by Gillete, et al(159). Fowler et al reported 
changes in BED by ~5% per 1% change in alpha/beta(196). It should be noted that the 
results from Chapter 2 suggest that uncertainty in the estimated mean dose to the LAD 
used to calculate the BED greatly exceeds the reported uncertainty due inaccurate 
estimates for the alpha/beta. Lastly, although the mean dose to the heart, LV, and LAD 
are comparable to the exposures observed in the breast cancer population; the distribution 
of the dose is different. In this study, a greater volume of the heart was exposed to low 
doses of radiation (< 1 Gy) in comparison to what is observed in breast patients treated 
with standard parallel opposed tangential beams.  
Although we consistently observed increases in cardiac uptake of 18F-FDG as a result of 
irradiation; a more complete histological analysis is needed to be certain that the increase 
in 18F-FDG post myocardial irradiation is due to cardiac inflammation. However, an 
inflammatory response to cardiac irradiation is strongly supported by previous studies in 
mice (48, 50, 51, 182). With regards to the validity of 18F-FDG PET for assessing 
inflammation, our group recently published a study using the same imaging protocol to  
assess inflammation following myocardial infarction (111) with correlation of in vivo 
FDG values with ex vivo measures of Indium labeled white blood cells. As indicated in 
the methods section of the study by Prato et al, the myocardial suppression protocol used 
to suppress myocardial glucose uptake was validated in a separate subset of 3 healthy 
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canines(111). Given that the same protocol was implemented here by the same team and 
using the same hardware, we are confident that the protocol was implemented correctly 
and equally reliable. Additionally, these results were consistent for all subjects which 
were imaged serially on separate days. Also, myocardial suppression was consistent and 
achieved in all animals at baseline; this is qualitatively supported by the minimal contrast 
between the LV blood pool and the myocardium on the baseline FDG images (see Figure 
4-3) and quantitatively by the very low SUV values in the myocardium, well below the 
values that are seen in images using glucose clamp techniques to augment myocardial 
uptake of FDG (see Figure 1-8).  
The cumulative dose to the heart from PET and CT imaging has been estimated using 
previously reported values(197) in conjunction with the average injected tracer activity. 
for this study to be ~0.2 mGy, 6.5 mGy, and ~6mGy for each 13N-ammonia, 18F-FDG, 
and each CT scan respectively. Thus the total cumulative dose from all 6 imaging 
sessions is approximately 1cGy which can be considered to have negligible impact on the 
current findings since it accounts for less than 1% of mean dose delivered to the heart 
from the medical LINAC.  
We reiterate the statement from Chapter 3 that although the study was performed using a 
hybrid PET/MRI scanner, all of the techniques presented can also be implemented using 
PET/CT. 
 
4.4 Conclusion 
The results of this study have demonstrated that 13NH3 and FDG PET can be used for the 
longitudinal assessment of myocardial perfusion and inflammation in association with 
cardiac external beam irradiation. Canine cardiac irradiation was designed to mirror the 
expected heart exposure associated with left-sided breast radiotherapy. In response to 
cardiac irradiation, progressive increases in FDG uptake, a non-invasive means of 
assessing inflammation, was observed and supported by ex-vivo histology in a single 
representative subject. A transient increase in myocardial stress perfusion that returned to 
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baseline levels (in 3 subjects) and below baseline levels (in 2 subjects) was observed.  
These findings alone do not yet provide conclusive support for or against the future use 
of 13NH3 and/or FDG PET imaging for the longitudinal assessment of the efficacy of 
treatment approaches previously proposed for reducing radiotherapy-related radiation 
induced cardiac toxicity in humans. A further longitudinal study is needed to identify an 
imaging parameter that is correlated with regional dose magnitudes and/or cardiac 
outcomes.  
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Chapter 5  
5 Conclusions and Future Work 
This chapter begins with a brief summary of the experiments, key results, and 
conclusions from previous chapters of this thesis. The summary is followed by revisiting 
the research questions and hypothesis that were initially proposed in the introduction (see 
section 1.7). A discussion of proposed answers to those research questions and the level 
of agreement between the initial hypothesis and the thesis results are provided. Lastly, we 
motivate future clinical and pre-clinical research projects that can further advance the 
findings of this work. Specifically, future projects that can 1) extend our fundamental 
understanding of the pathophysiology of radiation-induced cardiac toxicity; and 2) 
improve the clinical management/prevention of radiation-induced cardiac toxicity for 
breast cancer patients subjected to radiation therapy. 
5.1 Summary of Chapter 2 
This chapter provided an assessment of the effects of respiratory-induced cardiac motion 
on the ability to quantify the dose to the heart, left ventricle, and left anterior descending 
(LAD) artery during standard breast cancer radiotherapy planning.   
In breast cancer radiotherapy, the standard treatment planning approach uses a fast helical 
CT scan that cannot accurately capture the motion of internal organs caused by breathing. 
This is a concern for assessing dose to the heart since the anatomical position of the heart 
is influenced by respiration. In other clinical cases where internal motion amplitude is 
more pronounced (such as lung tumours) the fast helical CT is not appropriate. Rather, a 
helical CT scan with a much smaller couch pitch is used to capture multiple slice images 
over time. This technique is commonly referred to as a 4D-CT scan. The quasi-stalled 
translation of the couch through the CT allows for multiple ‘snapshot’ images to be 
acquired at the same axial slice position as a function of time. Additionally, during 4D-
CT imaging each axial image slice is tagged according to phase of the breathing cycle 
during the acquisition. Since multiple images are obtained at each axial slice, it is 
possible to retrospectively sort the images into multiple 3D volumes at multiple time 
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points in the breathing cycle. Information regarding the breathing cycle used for sorting is 
obtained from the motion of an external surrogate attached to the patient’s abdomen and 
monitored using wall-mounted cameras. Using 4D-CT and a non-rigid image registration 
algorithm, the planned radiation dose can then be warped in accordance to the motion of 
the internal anatomy.  
To assess the impact of respiratory motion on breast treatment planning, we compared the 
standard fast helical CT to the 4D-CT scan techniques (with dose warping) for 
calculating dose levels in of the heart, left ventricle, and LAD in 30 patients.     
The results of this study showed minimal impact of respiratory motion on the mean dose 
to the heart and left ventricle. However, substantial variation in dose due to respiratory 
induced motion was observed for the left anterior descending artery (95% CI: ± 8.7 Gy). 
We concluded that the fast helical CT could provide a good approximation for doses to 
the heart and left ventricle; however, future clinical studies attempting to assess the 
clinical impact of LAD irradiation should use 4D-CT derived dose estimates for 
improved accuracy.  
The study is unique in that it is the only published article (to the best of our knowledge) 
assessing the dose uncertainty due to respiratory motion on cardiac substructures (left 
ventricle and LAD) using the clinical imaging standard (fast helical CT). Previous studies 
using 4D-CT  have quantified dose to the heart as a whole(83, 84, 87, 88). The added 
value of reporting the variations in left-ventricle and the LAD dose due to respiration is 
supported in the literature(14). There is now ample mounting evidence that left-sided 
breast cancer survivors experience a higher risk of radiation induced ischemic heart 
disease, a disruption of the normal circulatory system of the heart(14, 17, 126). Thus, the 
importance of dose estimates specifically to the left ventricle and LAD is warranted as 
these are the main localized sites that include the micro and macro-circulatory systems of 
the heart. Additionally, our study is the largest known study (30 patients) examining the 
impact of respiration motion focused on the dose to heart substructures. The conclusions 
drawn from Ding, et al (87) and Yue, et al (88) are based on a small sample of 6 and 7 
left-sided breast cancer patients respectively.  
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 The results from this study were also critical in the design of a clinically-relevant 
radiation dose distribution for large animal (i.e. canine) studies presented in Chapter 3 
and Chapter 4. 
5.2 Summary of Chapter 3 
This chapter provided early, in-vivo, non-invasive assessment of myocardial perfusion 
and inflammation following focused cardiac irradiation in a canine model. Myocardial 
perfusion and inflammation were assessed using 13N-ammonia and 18F-FDG positron 
emission tomography imaging implemented on Canada’s first installation of hybrid PET-
MRI scanner. Using information from chapter 2, the delivered dose to the heart was 
designed to resemble typical cardiac exposures of left-sided breast radiotherapy. The 
radiation dose distribution was computed and delivered using clinical treatment planning 
software (Pinnacle3, Phillips) and a state-of-the art medical linear accelerator (Truebeam, 
Varian), respectively. Myocardial perfusion and inflammation scans were performed at 
baseline, 1 week, and 4 weeks following cardiac irradiation. Absolute quantification of 
perfusion was performed through tracer kinetic modeling. Similar to standard clinical 
assessments, myocardial perfusion was assessed at both rest and during adenosine- 
induced vasodilation. To visualize myocardial inflammation using 18F-FDG PET, image 
data were acquired after the suppression of normal myocardial glucose metabolism to 
avoid this confounding factor. 
The results of this study showed an increase in both myocardial perfusion and 
inflammation compared to baseline levels. Changes were observed at 1 week and 
remained elevated up to 4 weeks.  This functional response appeared to be global rather 
than local, affecting both more intensely irradiated and less-irradiated myocardial 
segments similarly. This finding is consistent with the observed lack of correlation 
between local dose levels and changes in perfusion and 18F-FDG uptake.  
To the best of our knowledge, the effects of cardiac irradiation at dose levels typically 
observed in the left-sided breast cancer population have not been previously studied using 
PET scans. The current findings are also supported by recently published results in a 
murine model(52). The majority of pre-clinical studies on radiation induced cardiac 
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toxicity have used murine models; however, here a large animal model of cardiac 
exposures is presented instead and the scaling allowed delivery of dose distributions 
comparable to human therapeutic exposures. The value added through the use of a large 
animal model provides easier translation of our findings into clinical practice.  The large 
animal model offers a more representatively sized  heart than murine models(150). 
Additionally, all previous nuclear imaging studies on the topic have used SPECT systems 
with qualitative analysis. Here, using cardiac PET, changes were observed very early as 
soon as 1 week post-radiation. This early observation is contrary to other imaging studies 
where changes could not be detected until at least 6 months (typically 18 months) post 
irradiation(45, 47).These findings are encouraging, however, future work is still needed 
to assess whether or not these PET findings are precursors to clinical end-points such as 
radiation-induced ischemia or if they are temporary effects of radiation that will resolve 
naturally. 
5.3 Summary of Chapter 4 
The fourth chapter of the thesis is a continuation of the third chapter. The same imaging 
techniques described in Chapter 3 were used to assess whether the early increases in 
perfusion and 18F-FDG uptake are transient or persistent effects of cardiac irradiation. All 
subjects were re-imaged at 3 months, 6 months, and 12 months using 13N-ammonia and 
18F-FDG on a hybrid PET-MRI scanner. At 12 months the animals were euthanized and 
their hearts were excised for ex-vivo histology. One sample subject was selected for 
haematoxylin/eosin staining and CD45 immunohistochemistry to assess cellular 
morphology and the presence of inflammatory cells, respectively.  A significant number 
of inflammatory cells were observed. However, histological analysis was preliminary as 
it was only performed in a single animal. Further analysis is needed to confirm the 
established presence and relative distribution of inflammatory cells within the left 
ventricle of the myocardium. 
The observed early increase in perfusion (seen in Chapter 3) relative to baseline was seen 
to be maintained up to 6 months post cardiac irradiation. At 12 months, the myocardial 
stress perfusion estimates returned to baseline in 3 subjects and dropped below baseline 
in the remaining 2. A significant correlation could not be found between the magnitude of 
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perfusion changes and local dose deposition.  To the best of our knowledge, early 
increases in perfusion following cardiac irradiation have not been observed previously. 
However, past myocardial perfusion studies following cardiac irradiation have been 
limited to qualitative cardiac SPECT imaging at much later time points,  6 months post 
irradiation(43, 45, 177, 198). This novel finding is supported by experimental studies in 
mice showing increases in vascular permeability, increases in vascular endothelial cell 
proliferation markers, and a transient increase in capillary density within 20 – 40 weeks 
following cardiac irradiation (19, 125, 182).  These fundamental radiobiological 
mechanisms support and may explain our PET imaging observations at early time points. 
Statistically significant increases in 18F-FDG myocardial uptake at 3 months, 6 months 
and 12 months post irradiation were observed.  Unlike perfusion, the uptake of 18F-FDG 
gradually increased with time and does not appear to be resolving to baseline levels. The 
early increases in 18F-FDG myocardial uptake (seen in Chapter 3) relative to baseline do 
not therefore appear to be temporary; this response is persistent in all animals over the 
course of this 12 month study. This response to cardiac irradiation also appears to be 
global. A significant correlation could not be found between the magnitude of 18F-FDG 
uptake changes and the local dose deposition. These findings are novel, but a more 
complete histological analysis is still needed to assess whether the lack or correlation is 
due to a true global inflammatory response or limitations in hardware sensitivity. To the 
best of our knowledge, a non-invasive 18F-FDG PET imaging assessment of 
inflammation in which myocardial glucose metabolism is co-suppressed has not been 
previously used following cardiac irradiation levels relevant to breast radiotherapy. An 
inflammatory response to cardiac irradiation has been previously reported using ex-vivo 
techniques in mice(33, 50, 52). Attempts to correlate regional dose to inflammation is not 
currently possible in mice due to the small size of the heart. The findings from Chapter 4 
are based on a much larger heart specimen and strongly support the clinical use of PET 
for a more timely assessment of treatment strategies aimed at reducing radiation induced 
ischemia. 
The key results from Chapters 3 and 4 have been combined in Figure 5-1. 
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Figure 5-1: The temporal progression of 18F-FDG standard uptake (panel A), 13N-
ammonia rest perfusion (panel B), and stress perfusion (panel C) within the left 
ventricle myocardium. Results are grouped by myocardial regions supplied by the 
left anterior descending (LAD) and/or the left circumflex (LCX). The estimated dose 
delivered is reported in the legend; error bars indicate the standard error of the 
mean. 
5.4 Conclusions 
In Chapter 1, the goal of this thesis was motivated with the following previously 
unanswered research question: 
1. Does respiratory motion impact left-side breast cancer radiotherapy planning in 
terms of the accuracy of estimating doses to the heart, left-ventricle, and left 
anterior descending artery? 
2. Can the effects of heart, left ventricle, and left anterior descending artery 
irradiation on myocardial perfusion and inflammation be visualized using PET at 
dose magnitudes comparable to modern left-sided breast radiotherapy?  
3. Can the effects of cardiac irradiation be visualized using PET at earlier time 
points in comparison to other previously used imaging modalities? 
4. Is there a spatial relationship between the magnitude of dose and regional changes 
in cardiac inflammation? 
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5. Is there a spatial relationship between the magnitude of dose and regional changes 
in cardiac perfusion? 
6. Are specific regions within the heart, such as arteries, more sensitive to radiation 
effects than others?   
Question 1 was answered in Chapter 2 of this thesis. The answer to this question is “yes” 
for the LAD and left ventricle but not for the heart. Using detailed 4D-CT scan data we 
showed that respiratory motion had the most significant dosimetric impact on the LAD 
(±8.7 Gy). The magnitude of the variations in dose to the heart (±0.5 Gy) and left 
ventricle (±1.0 Gy) were much smaller. Additionally, the findings in the heart zone may 
be considered negligible since they are on the same order of magnitude as previously 
reported uncertainties due inter-observer variations in heart delineation(136). These 
findings also agree with our first hypothesis: “A significant variation in dose across heart 
structures is attributable to respiratory-induced motion during left-breast cancer 
radiotherapy.” 
Question 2 was answered in Chapters 3 and 4 of this thesis. The answer to this question 
is “yes”. PET can measure the effects of cardiac irradiation on perfusion and 
inflammation. We have shown statistically significant changes relative to baseline in 
myocardial perfusion and 18F-FDG uptake (indicative of inflammation) using PET.  
Question 3 was answered in Chapter 3 of this thesis. The answer to this question is also 
“yes”. PET can visualize the effects of cardiac irradiation at earlier time points in 
comparison to previously published more qualitative imaging studies using other 
modalities such as SPECT. In Chapter 3 we measured a statistically significant increase 
in both myocardial perfusion and 18F-FDG PET as early as 1 week post cardiac 
irradiation. A caveat for this answer is that previous SPECT studies were performed in 
breast cancer patients not a canine model. Although the canine model is routinely used 
for cardiac studies, further study is needed to determine whether the temporal response to 
radiation is different than what is observed in humans. For a definitive answer a humans 
study using PET is proposed as future work  
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Question 4 and Question 5 were answered in Chapters 3 and 4 of this thesis. The answer 
to this question based solely on the results from this thesis is “no”. Both the perfusion 
changes and 18F-FDG uptake changes were not correlated with the spatial dose 
distribution. The effects of cardiac irradiation appeared to be more global, affecting both 
more irradiated and less irradiated segments similarly. A global response to focal cardiac 
injury is not a unique finding to this study. Others have observed considerable 
inflammatory cell recruitment in myocardium remote from the myocardial 
infarction(199). Furthermore, there is published evidence in other organs of a remote 
response in non-irradiated regions adjacent to irradiated regions, this is commonly 
referred to as the “bystander effect”(200, 201). That being said, it is a possibility that a 
correlation could be found given a larger sample size of animals; however, this is purely 
speculative. In addition to a greater sample size, perhaps a steeper dose gradient would 
yield a greater dose “spread” across myocardial regions for comparison. This may be 
relevant if 18F-FDG PET may not have the sensitivity or specificity to detect potentially 
subtle variations between myocardial regions irradiated by 9 Gy vs 1 Gy. Further study is 
needed prior to completely ruling out the presence of a relationship between dose 
magnitude and perfusion/inflammation changes.  
In an attempt to answer Question 6, the dose distribution used in Chapters 3 and 4 was 
designed such that cardiac function could be assessed in localized regions where 1) the 
tissue and supplying artery were both focused with radiation; 2) only the tissue focused 
but the supplying artery was minimally irradiated; and 3) the tissue and the supplying 
artery were minimally irradiated. All three regions showed a similar response. Due to the 
global response to cardiac irradiation, the radio-sensitivity of the left ventricular tissue 
and the coronary arteries appear to be similar.    
Our findings only partially agree with our second hypothesis: “A reduction in left 
ventricular perfusion and an enhancement in inflammation are related to local radiation 
dose levels within the heart.” 
The observed increase in 18F-FDG was expected due to previous reports showing 
increases in inflammation in response to cardiac irradiation(52).The increase in FDG is in 
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agreement with our hypothesis; however, the result differs from the hypothesis in that it 
was a systemic increase in FDG as opposed to one which is proportional to the dose 
magnitude.   
To the best of our knowledge the observed transient increase in perfusion has not been 
previously observed. We suspected that cardiac irradiation would lead to a gradual 
decline in perfusion. Declines in perfusion are hypothesized to be due to functional 
damage to the microcirculation supported by previous SPECT perfusion studies(198). 
Alternatively, the delivered cardiac doses in this study resulted in a reversed response by 
the microcirculation. Although this was unanticipated, it may partly explain the 
discrepancy with previously published SPECT perfusion studies. Perhaps the detection of 
perfusion defects can only occur after the initial “survival response” has subsided. This 
may explain the lesser incidence of cardiac perfusion defects at 6 months (27%) vs 24 
months (42%) post radiotherapy(198). Lastly, the transient increase in perfusion followed 
by a decrease at 12 months is supported by a recent pre-clinical study in mice showing a 
transient increase in capillary density (+6-24%) at 20 weeks post radiation preceding a 
decline at 60 weeks (182). 
5.5 Future Work 
5.5.1 Clinical PET assessment of radiation induced cardiac 
toxicity following left-sided breast cancer radiotherapy  
A natural continuation of the work presented in this thesis would be an extension to apply 
the dose planning and imaging techniques to a sample of left sided breast cancer patients. 
We propose a longitudinal study in humans comparing efficacy of alternatives to standard 
parallel opposed radiotherapy treatment (alternatives were previously discussed in section 
1.5). The use of baseline and 1 week/4 week post radiotherapy PET imaging is proposed 
to assess cardiac inflammation in these patients. We hypothesize that patients showing 
reduced inflammation on PET will be less susceptible to future radiation induced 
ischemia. Unfortunately, this hypothesis cannot be assessed without long-term patient 
follow-up (10-15 years post radiotherapy).  
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Since it is well documented that inflammation often precedes tissue fibrosis(42), 
inflammatory response in a cohort of patients could be counteracted  through the use of 
clinically approved anti-inflammatory medication (ie ACE inhibitors). Although ACE 
inhibitors are primarily used to treat hypertension, they’ve also been shown to have anti-
inflammatory(202) and free radical scavenging properties(193). The use of ACE 
inhibitors to reduce radiation-induced cardiac damage has shown promise in a recent 
mouse study(176). Translation of these findings to humans would benefit significantly 
from a non-invasive means of assessing local cardiac inflammation such as 18F-FDG 
PET. 
5.5.2 Incorporating breathing induced cardiac motion information 
in left-sided breast cancer radiotherapy planning to reduce 
cardiac exposures  
Many studies have shown that breathing-adapted radiotherapy ( respiratory gating or 
breath-holds) can provide significant reductions in cardiac exposures (56). However, 
these approaches can significantly increase the complexity and duration of planning and 
treatment of patients. Treating all breast cancer patients with this approach will likely 
reduce patient throughput and delay treatments. Furthermore, a recent study has shown 
that for some patients, breathing-adapted radiotherapy may lead to worse cardiac function 
than what is observed with the standard treatment approach(142). This problem motivates 
the search for an approach to quickly stratify patients most likely to benefit from 
breathing adapted radiotherapy.   
Currently, two stratification criteria have been previously published: 1) stratification 
based on the distance between the heart/LAD to a line segment spanning the sternum and 
the mid-lateral edge of the body, referred to as mean heart depth(84),  and 2) stratification 
based on a dose-volume threshold (apply breath-holds if the standard treatment plan 
results in more than 10 cm3 of the heart to be exposed to 25 Gy or more)(149). Although 
conceptually simple to implement, the use of the mean heart depth for stratification has 
not been widely accepted due to its poor correlation with the actual measured dose to the 
heart and LAD (reported R2< 0.12) (84). The dose volume constraint proposed for 
stratification by Wang, et al is derived from results from a previous study(47). Lawrence, 
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et al, showed that the incidence of perfusion defects increased significantly (from 10-
20% to 50-60%) for patients with >5% of the left ventricle exposed to at least 25 Gy(47).  
Unfortunately, implementing this dose-volume constraint for stratification requires a 
complete radiotherapy treatment plan to be created prior to making the decision. Unless 
centres can automate the task of creating breast radiotherapy plans, this method may 
significantly increase the treatment planning workload and lead to delays in patient 
treatments.  
A future study where each patient’s breathing-induced cardiac motion is characterized is 
likely needed to establish better patient selection guidelines.  For example, the impact of 
breathing motion is routinely characterized in lung cancer treatment planning through the 
use of 4D-CT. In lung cancer radiotherapy planning, the motion derived from the 4D-CT 
is used to create an internal target volume that encompasses the full range of tumour 
motion. We have shown in Chapter 2 that 4D-CT can also similarly be used to 
characterize the dosimetric impact of heart, left ventricle, and LAD motion. The ability to 
characterize the motion of the heart and LAD, can potentially lead to patient specific 
motion margins for these organs as well. Future studies may choose to investigate the 
role of cardiac motion margins created for avoiding the heart, left ventricle, and LAD at 
all possible phases of the breathing cycle. Without further investigation, the fast helical 
CT will likely continue being the clinical standard for breast radiotherapy planning and 
the effects of breathing on heart dose will continue to be ignored until 4D CT is 
implemented routinely. 
5.5.3 Potential improvements in radiation induced cardiac toxicity 
models  
Pre-clinical research is still needed to help us better understand the underlying patho-
physiology of radiation induced cardiac toxicity. The relationship between dose 
magnitude and cardiac injury is still not well understood and raises questions about local 
and global response outside the irradiated zone. Previous proposals that cite a 7.4% 
increase in the rate of a major coronary event per 1 Gy dose to the heart may not be 
relevant today since this relationship was derived from obsolete breast cancer treatment 
techniques between the year 1958 and 2001(17). In addition, today’s patients receive 
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adjuvant therapy, combining radiation with new chemotherapy agents not previously 
used until the early 2000’s. The relevance of this to radiation-induced cardiac toxicity is 
motivated by evidence linking chemotherapy with severe cardiac disorders(203–205). 
Anthracyclines (FDA approval in early 1970’s) and trastuzumab (FDA approval in late 
1990’s) are two breast cancer chemotherapy agents that are commonly used and have 
been shown to negatively impact cardiac function. The effects of anthracyclines on 
cardiac function are well documented(206–208). Swain, et al, reviewed the literature and 
concluded that the cumulative percentage of patients with anthracycline-related 
congestive heart failure was between 5% - 26% (206). Anthracyclines have been shown 
to cause a buildup of reactive oxygen species that directly damage mitochondrial DNA 
within cardiomyocytes inducing cell death(209).  This effect is similar to radiation-
induced oxygen effects and may be compounded by chemotherapy activation. 
Anthracyclines directly damage cardiomyocytes, however, trastuzumab is believed to 
indirectly impact the cells through the disruption of the repair process(210). Furthermore, 
it is believed that these cardio toxic effects are even greater for patients with significant 
cardiac irradiation(211).  
In light of this, future animal models attempting to study the relationship between cardiac 
toxicity and radiation should also include anthracyclines and trastuzumab. Here, we have 
shown the utility of PET for assessing cardiac response to radiation alone, however future 
PET studies should include the combined effects of chemotherapy and radiation.  
5.5.4 Cardiac radio-sensitivity and setting clinical guidelines for 
“safe” exposure levels  
It has been previously hypothesized that the radio-sensitivity of the heart is 
heterogeneous, meaning that some parts of the heart respond differently to radiation 
exposure than other regions. This heterogeneity in sensitivity has been observed in 
preclinical studies comparing the effects of coronary artery irradiation versus left 
ventricle irradiation(15, 18). Coronary artery irradiation has been shown to cause an 
acceleration of the formation of plaques that are  prone to rupture(33). The left ventricle 
tissue is highly vascularised and irradiation of this structure leads to significant decline in 
the local functional capillaries(182). Both these effects are not mutually exclusive and 
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can lead to myocardial ischemia and infarction. Safe dose limits for each of these specific 
cardiac substructures are not yet known. In light of this, the current guidelines based on a 
single dose value (i.e. mean heart dose) may be a gross oversimplification.    
Both dose magnitude and irradiated volume need to be considered when setting dose 
tolerance levels for organs. For the heart it is not known whether a low dose delivered to 
a large volume is less harmful than a high dose to a small volume.  It has been 
hypothesized that the functional integrity of the coronary arteries is analogous to a chain. 
In other words, these arteries may constitute a radiobiological “serial organ” and the 
functionality of all of the subunits that make up the artery must be maintained. The 
radiation tolerance of serial organs such as the spinal cord depends on the magnitude of 
local dose delivered to a sub-unit than the total irradiated volume.  Conversely, parallel 
organs such as the lungs and kidneys have a considerable functional reserve capacity; 
meaning they can still function normally even when small fraction of the organ is 
damaged. The microcirculation of the heart is housed in the left ventricles and has 
significant functional reserve capacity, supporting the hypotheses that unlike the artery it 
will behave as a parallel organ. Setting exposure guideline for the heart is therefore 
complicated because it is functionally dependent on both the major coronary arteries 
(serial organs) and the left ventricular tissue (parallel organ).  
Future studies attempting to assess exposure guidelines for cardiac sub-units such as the 
coronary arteries and left ventricles should be performed in large animal models not 
mice. With the large animal models the heart is large enough to allow for more focused 
irradiation of the arteries and/or left ventricular tissue. Such a study can potentially lead 
to separate dose limits for the arteries and the left ventricle replacing or augmenting the 
current use of the total mean heart dose. In summary, we continue to propose that a large 
animal model should be used to mimic clinically-relevant dose levels and dose 
distributions giving opportunity to distinguish serial and parallel responses. 
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5.5.5 Hybrid PET-MRI imaging of radiation induced cardiac 
toxicity  
Although this thesis used a hybrid PET-MRI system to assess cardiac function following 
radiation exposure, only PET findings were reported and used in our studies. As 
previously discussed (sections 1.6.5), the MRI compliments the PET system by adding 
both additional functional imaging options and anatomical context. Also, since PET-MRI 
systems can acquire images simultaneously, the imaging protocol implemented in 
Chapter 3 and Chapter 4 can be significantly reduced by assessing perfusion using 
dynamic contrast enhanced MRI while simultaneously assessing inflammation with 18F-
FDG PET. Decreasing the imaging session duration is important for maintaining 
compliance when attempting to translate animal research to humans. Furthermore the use 
of MRI is more suitable for longitudinal human studies due to the reduction in radiation 
doses to the patient compared with PET imaging alone. Lastly, in addition to assessing 
perfusion with MRI, the system can determine the potential presence of radiation-induced 
edema, wall motion abnormalities, and fibrosis. To the best of our knowledge in-vivo 
assessment of radiation induced cardiac edema and fibrosis has not been fully quantified 
using MRI. Edema and fibrosis are two additional sub-clinical end points that may be 
used for assessing radiation induced cardiac toxicity mitigation strategies in humans.      
It is hoped that the imaging and dosimetric findings reported in this thesis will assist in 
developing novel cardiac toxicity reduction strategies that will enhance complication-free 
survival of breast cancer patients subjected to the benefits of effective adaptive 
radiotherapy. 
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Appendix B: Worked general solution to equation 1-1 
 
 𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)
𝑑𝑡
= 𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) −  𝐾2𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) 
1-1 
begin by taking the Laplace transform of both sides of equation 1-1 
 
𝐿 {
𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)
𝑑𝑡
} = 𝐿{𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) −  𝐾2𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡)} 
 
in the Laplace domain we have the following equation 
 𝑠𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) − 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(0) = 𝜌𝐾1𝐶?̅?𝑙𝑜𝑜𝑑(𝑡) − 𝐾2𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) A-1 
where 𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) 𝑎𝑛𝑑 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(0) are the Laplace transform of 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 and the initial 
condition in the time domain respectively. Since the initial condition is equal to zero we 
can rearrange equation A-1 to solve for  𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) 
 𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) =
𝜌𝐾1?̅?𝑏𝑙𝑜𝑜𝑑(𝑡)
𝑠+ 𝑘2
  
 𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡) = 𝜌𝐾1𝐶?̅?𝑙𝑜𝑜𝑑(𝑡)
1
𝑠+ 𝑘2
  
The following equation is obtained by taking the inverse Laplace transform of both 
sides. Also, recall that multiplication in the Laplace domain is convolution in the time 
domain. 
 𝐿−1{𝐶?̅?𝑖𝑠𝑠𝑢𝑒(𝑡)} = 𝐿
−1{𝜌𝐾1𝐶?̅?𝑙𝑜𝑜𝑑(𝑡)} ⊗ 𝐿
−1 {
1
𝑠+ 𝑘2
}  
 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) = 𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑(𝑡) ⊗ 𝑒
−𝐾2𝑡  
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Appendix C: Summary of patient treatment characteristics 
Treatment Description Prescribed Radiation Dose 
Number of 
Patients 
Whole Breast POP   
 Standard 50 Gy in 25 7 
  42.5 Gy in 16 6 
 + Boost 50 Gy in 25; 10 Gy in 5 3 
  42.5 Gy in 16; 10 Gy in 5 4 
 + SCLAV 50 Gy in 25 2 
 + Boost; + SCLAV 50 Gy in 25; 10 Gy in 5 1 
 + IMC 42.5 Gy in 16 1 
 +IMC; +SCLAV 50 Gy in 25 1 
Chest Wall POP   
 +SCLAV 50 Gy in 25 3 
 +SCLAV; +IMC 50 Gy in 25 2 
Abbreviations: POP: tangential parallel opposed photon beams; SCLAV: supraclavicular 
irradiation; IMC: internal mammary chain irradiation (wide tangential parallel opposed photon 
beams); *all delivered using photons ( 6MV or 6MV & 18 MV Fields) 
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Appendix D: Animal Ethics Approval 
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Appendix E: Summary of multi-fractionated and BED corrected single fraction 
radiation dose constraints to the heart obtained from clinical patient data. 
  Standard 
Multi-Fractionated 
patient derived data 
 
Biological Equivalent 
Dose (BED) 
 
Single Fraction Delivery 
Dose Constraints 
  Mean 95% CI  mean 95% CI  mean 95% CI 
Heart         
 mean dose (Gy) 2.3 [1.7, 3.0]  2.4 [1.7, 3.1]  1.5 [1.2, 1.8] 
 V50 (cm3) 18.4 [9.2, 27.6]  - -  - - 
Left ventricle         
 mean dose (Gy) 3.1 [2.2, 4.2]  3.4 [2.3, 4.5]  1.2 [1.4, 2.3] 
 V50 (cm3) 6.5 [2.6,10.5]  - -  - - 
LAD          
 mean dose (Gy) 11.9 [8.6, 15.3]  14.2 [9.8, 19.0]  4.8 [3.8, 5.8] 
 D0.4 (Gy) 28.8 [17.5, 30.2]  42.1 [22.4, 44.8]  9.1 [6.3, 9.4] 
Abbreviations: CI: confidence interval; V50: volume of organ receiving at least 50% of the prescribed 
dose; D0.4: maximal dose to 0.4 cm3 of the organ; LAD: left anterior descending artery. * α/β ratio used 
for BED calculation was 2.5 Gy (Gillette S, et al. Radiother. Oncol. 1992;23:41–52) 
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Appendix F: Summary of experimental details and cardiac dose distribution 
 
PGL 
(mmol/L) 
injected radiotracer 
activity 
(MBq) 
cardiac dose distribution 
mean dose (Gy) 
  13Nstress 13Nrest 18FDG Heart LV LAD LCX 
Subject 1     1.9 3.0 6.8 0.8 
 baseline 6.4 107 106 100     
 1 week 5.6 105 102 101     
 4 week 4.4 100 104 96     
 3 months 4.7 95 51 94     
 6 months 5.3 108 106 108     
 12 months 6.2 85 104 103     
Subject 2     1.6 2.5 4.7 0.9 
 baseline 4.8 104 104 110     
 1 week 4.6 97 96 97     
 4 week 3.5 106 105 98     
 3 months 5.6 103 106 91     
 6 months 4.5 116 74 114     
 12 months 5.8 91 110 97     
Subject 3     1.5 2.4 5.7 1.2 
 baseline 6.2 101 106 96     
 1 week 6.2 100 101 103     
 4 week 4.9 90 102 114     
 3 months 4.7 85 89 98     
 6 months 4.7 143 108 103     
 12 months 5.9 100 100 110     
Subject 4     1.8 2.6 5.6 1.7 
 baseline 5.2 102 112 94     
 1 week 5.2 101 106 110     
 4 week 4.9 105 101 100     
 3 months 4.5 90 103 109     
 6 months 4.6 84 105 112     
 12 months 5.2 111 95 90     
Subject 5     1.9 2.9 4.7 0.8 
 baseline 6.3 95 114 111     
 1 week 5.9 98 88 100     
 4 week 5.6 108 106 105     
 3 months 4.8 103 97 107     
 6 months 5.8 100 107 107     
 12 months 6.1 109 108 104     
mean 5.3±0.1 101±2.3 100±2.5 103±1.4 1.7±0.1 2.7±0.1 5.5±0.3 1.1±0.2 
Abbreviations: PGL: plasma glucose level; 13Nstress: ammonia injection during pharmacological stress perfusion; 13Nrest: ammonia injection 
during rest perfusion; LV: left ventricle; LAD: left anterior descending artery; LCX: left circumflex artery. All data presented as mean ± 
standard error of mean. Since the radioactive decay follows a Poisson distribution, the expected standard deviation in the individual tracer 
activities is equal to the square root of the measured activity. 
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